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CNS (Central Nerves System) injuries, caused by many reasons, usually lead to 
the permanent paralysis of patients because the transected axons in CNS could not 
regenerate beyond the lesion site. 16 erythropoietin-producing hepatocellular (Eph) 
kinases constitute the largest family of the receptor tyrosine kinases, which are 
activated by 9 membrane-associated ephrin ligands. Interactions between Eph 
kinases and ephrins have been extensively investigated for their developmental 
roles in axon guidance, topographic mapping, hindbrain segmentation etc. For 
example, EphA5 is characterized as an axon guidance molecule during neural 
development and also engaged in inhibition of the neurite outgrowth of the 
hippocampal, striatal, retinal and cortical neurons. Another Eph receptor, EphA7, 
is involved in gastric colon, prostate cancers, non-small cell lung cancer and acts 
as a tumor suppressor in follicular lymphoma. To understand the structural basis 
underlying their very diverse functions, we first solved the crystal structures of 
EphA5 and EphA7 ligand binding domains, followed by mapping their dynamic 
properties on different time scales, as well as interactions with peptides and small 
ligands by NMR spectroscopy.  
Mammalian adult CNS failed in axon regeneration, while fish CNS is capable 
of axon regeneration. Nogo-66 is an important region of Nogo proteins with 
multiple functions, especially in inhibiting of human CNS axonal regeneration. 
  VII 
Fish Nogo-66 was thought to be different, so that it does not impair axon 
regeneration. Thus, the structure of its buffer-soluble form, Nogo-54 in Medaka 
fish was solved by NMR spectroscopy and subsequently compared with the NMR 
structure of the human Nogo-54.  
These findings may help in design and optimization of peptides and small 
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CHAPTER I. Introduction 
1.1 Biological Background 
1.1.1 Central Nervous System 
Human nervous system consists of two parts, central nervous system (CNS) 
and peripheral nervous system (PNS).  The central nervous system contains 
majority of the nervous system including brain, spinal cord and retina. It has a 
fundamental and important role in control of behaviors of human body. So once 
the central nervous system is damaged, it can be a fatal illness. 
The common causes of central nervous system diseases are: trauma, 
infections, degeneration, structural defects, tumors, autoimmune disorders, stroke 
etc. Any one of them can result in a wide spectrum of disabilities of human beings. 
Worldwide people suffered from central nervous system illness: the consequences 
of trauma including memory loss, speech problems; the CNS diseases including 
Alzheimer’s, Parkinson's and many other diseases. For example, over 35 million 
people in the world have Alzheimer’s disease, which is a neurodegenerative 
disease typically found in people over the age of 65 years 
(Alzheimer's-Association, 2011). The cause of Alzheimer’s is still unknown and 
there is no cure for this disease. Therefor, it is quite critical and urgent to 
investigate CNS diseases and develop the medical therapies for them. 
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1.1.2 Axonal Regeneration and Inhibitory molecules 
 Due to the failure of central neurons to regenerate dendritic connections and 
correct axonal, CNS injury does not only cause a break in communication between 
healthy neurons, it also lead to neuronal degeneration and cell death (Horner and 
Gage, 2000). It was shown decades ago, unlike fish, amphibian and mammalian 
peripheral nervous system, adult central mammalian nervous system is unable to 
regenerate functional axons after injury (Ramon y Cajal, 1928). While after 
implanted to peripheral nervous system tissues, neurons of central nervous system 
would grow, suggesting that it might be the environment, not the neuron, that is 
prevent the regeneration within central nervous system (David and Aguayo, 1981; 
Tello, 1911). The mechanism for inability of neuron regeneration of injured CNS 
has been extensively investigated over the past several decades, while it is still 
unclear.  
 Although not all of the mechanisms for the failure of CNS neurons 
regeneration have been clarified, one hypothesis that CNS has inhibitory 
molecules that can block axonal regeneration has been approved. Caroni, Schwab 
and Savio (1988) first found that CNS contains actual growth inhibitors (Caroni et 
al., 1988; Caroni and Schwab, 1988). Since 1988, several other factors have been 
identified to be capable of inhibiting the regeneration. The identified inhibitory 
molecules include the chondroitin sulfate proteoglycans (CSPG) Neurocan, 
Brevican, Phosphacan, Tenascin, and NG2, as either membrane-bound or secreted 
molecules; Ephrins expressed on astrocyte/fibroblast invading the scar; and the 
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myelin-associated inhibitors Nogo, MAG, and Omagp (Sandvig et al., 2004).  
 My thesis mainly emphasizes EphA5/EphA7, receptors of ephrins, which 
involved in neuron regeneration and many other functions; and Nogo-66, an 
important domain of Nogo derived from Medaka fish. 
 
1.1.3 Eph Family 
 One of the largest receptor tyrosine kinases families identified to date is the 
erythropoietin-producing hepatocellular carcinoma (Eph) family, which is divided 
into two subclasses, A and B, based on their binding preferences and sequence 
conservation (Eph-Nomenclature-Committee, 1997). There are 16 structurally 
similar family members, 10 EphA receptors (EphA1- EphA10) and 6 EphB 
(EphB1- EphB6) receptors. In general, EphA receptors bind to glycosyl 
phosphatidyl inositol (GPI) – anchored ephrinA ligands (ephrinA1- ephrinA6), 
whereas EphB receptors interact with transmembrane ephrinB ligands (ephrinB1- 
ephrinB3); interactions between Eph receptors and ephrins within each A or B 
subclass are quite promiscuous with various binding affinities. Interactions 
between different subclasses are relatively rare, except that EphA4 can bind to all 
three ephrinB ligands and EphB2 can bind to ephrinA5 ligand (Gale et al., 1996; 
Pasquale, 2008; Qin et al., 2008).  
 Eph receptors have a modular structure that consists of a conserved 
N-terminal ephrin binding domain adjacent to a cysteine-rich domain and two 
fibronectin juxtamembrane domains, followed by a conserved tyrosine kinase 
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domain, a C-terminal sterile a-domain, and a PDZ binding motif (Figure 1.1.1). 
The N-terminal 180 amino acid globular domain is sufficient for high-affinity 
ligand binding. The adjacent cysteine-rich domain might be involved in 
receptor-receptor oligomerization often observed on ligand binding according to 
previous study (Pasquale, 2005; Qin et al., 2008). 
 
Figure 1.1.1: Eph receptor and ephrin domain structure and signaling 
interactions (Pasquale, 2010).  
  
The direct protein-protein interactions between ligands carrying signals, and 
cell-surface receptors recognizing and transforming the information into the 
receiving cells are the key methods of the communication between cells (Himanen 
et al., 2001). Communications of biochemical signals between cells are crucial for 
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the development and existence of multicellular organisms. The Eph/ephrin family 
is one of the largest groups of receptors and ligands that are able to emanate 
bidirectional signals: forward signals propagate in the receptor-expressing cells 
depended on the tyrosine kinase domain activity upon ephrin binding, and reverse 
signals to the ligand-expressing cells (Flanagan and Vanderhaeghen, 1998; 
Himanen and Nikolov, 2003; Himanen et al., 2007; Holland et al., 1996; 
Kullander and Klein, 2002; Pasquale, 2005). The members of Eph/ephrin family 
play important and different roles in both developing and adult tissues. For 
example, previous studies showed that the Eph-ephrinB interactions involved in 
mediating neuronal regeneration, learning and memory formation, pain processing, 
and differential expression levels of ephrinB are also correlated with tumor 
genesis (Battaglia et al., 2003; Ran and Song, 2005). Eph receptors have been 
most extensively studied for their developmental roles in biological processes 
such as hindbrain segmentation, tissue patterning, vascular system development, 
axonal guidance, and neuronal development (Brantley-Sieders and Chen, 2004; 
Palmer and Klein, 2003; Pasquale, 2005, 2008; Wilkinson, 2001). They also play 
roles in immunity, bone remodeling, blood clotting and stem cells (Edwards and 
Mundy, 2008; Matsuo, 2010; Prevost et al., 2002; Prevost et al., 2004; Yu et al., 
2004). 
 
1.1.4 Structures of Eph Receptors and Eph/ephrin Complexes 
 The structural study of the Eph receptors and complexes with their ligands 
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will help us understand the recognition and interaction between Eph receptors and 
their ligands to further explain the important and different functional roles they 
played in various biological processes. The ligand-binding domains of EphA2, 
EphA4, EphB2 and EphB4 in unbound state and in complex with ephrins or 
peptides have been solved by X-ray crystallography (Chrencik et al., 2006a; 
Chrencik et al., 2006b; Chrencik et al., 2007; Himanen et al., 2004; Himanen et al., 
2009; Himanen et al., 1998; Himanen et al., 2001; Qin et al., 2008). These 
previous studies showed that despite of different subclasses of Eph receptors they 
belong to, all the Eph receptor ligand-binding domains adopt a conserved jellyroll 
β-sandwich architecture that are composed of 11 antiparallel β-strands connected 
by loops of various lengths. The ectodomain of the ephrin ligands also showed a 
conserved structure, which is consist of an eight-stranded β-barrel with a Greek 
key topology, linked by several very flexible and highly conserved functional 
loops, such as the G-H and C-D loops (Himanen et al., 2004; Himanen et al., 2009; 
Himanen et al., 2001; Toth et al., 2001). 
From the crystal structures of Eph receptor ligand-binding domains and 
ephrin ligands complex, it is showed that through the penetration of an extended 
G–H loop of the ephrin ligand into a hydrophobic channel on the surface of the 
receptor, Eph receptors are capable of binding to ephrin with high affinity. The 
convex sheet of four β-strands surrounded by the D-E, G-H and J-K loops forms 
the high-affinity binding channel (Himanen et al., 2009). There are three other 
interfaces also contribute to Eph-ephrin binding, including: (1) additional residues 
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on both the receptor and ephrin surfaces; (2) a low affinity interface also involving 
the Eph receptor ligand-binding domain, which was identified in the 
EphB2-ephrinB2 complex and appears to mediate the association of two 
receptor-ephrin dimers (tetramerization) (Himanen et al., 2001); (3) an interface 
involving the cysteine-rich region adjacent to the ligand-binding domain, which 
was identified by mutagenesis in the EphA3-ephrinA5 complex but has not been 
structurally characterized and which might be implicated in high order clustering 
(Smith et al., 2004).  
Two binding interfaces have been found from the structure of 
EphB2-ephrinB4 complex: the first one is the high affinity ligand-binding channel 
of EphB2 receptor which is formed by the flexible J-K, G-H, and D-E loops, 
located at the upper convex surface of EphB2, accommodated the solvent-exposed 
ephrin G-H loop upon Eph-ephrin binding; another low affinity binding interface, 
which interacts with the C-D loop of ephrinB4 has also been identified at the 
concave surface of the receptor H-I loop to mediate two receptor-ephrin dimers 
tetramerization (Chrencik et al., 2006b). 
The structure of EphA2/ephrinA1 heterodimer is architecturally similar to 
EphB2-ephrinB4 complex structure. The ligand/receptor interface centers around 
the G–H loop of ephrinA1, which is inserted in the traditional ephrin-binding 
channel on the surface of EphA2. Eph receptor strands D, E, G, J and M, define 
the border of this channel. A second contact area, which is adjacent to the 
channel/G–H-loop interactions but structurally separated, was found to encompass 
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the ephrinA1 docking site along the upper surface of the receptor. Here, the ephrin 
β-sandwich consisted of strands C, G and F interacts with EphA2 strands D, E and 
the B-C loop region through a network of hydrogen bonds and salt bridges 
(Himanen et al., 2009). 
Although Eph receptors interact promiscuously with ephrin ligands of the 
same subclasses, interactions of Eph receptors with ephrin ligands of the different 
subclasses are quite rare. EphA4 receptor is one exception that can interact with 
all three ephrinB ligands. The overall architecture of the EphA4-ephrinB2 
complex is very similar to other Eph-ephrin complexes. The high affinity interface 
of the complex can be divided into two relatively independent regions. One mostly 
involves hydrophobic interactions between the EphA4 ligand-binding channel and 
the ephrinB2 G-H loop. The other, which was observed in EphB-ephrinB 
complexes (Chrencik et al., 2006a; Himanen et al., 2001) but was greatly reduced 
in the EphA2-ephrinA1 complex and absent in the EphB2-ephrinA5 complex 









 in ephrinB2.  
Comparison of these released structures of unbound Eph receptors or in 
complexes with their ephrin ligands yields insight into the molecular basis for 
observed Eph receptor/ephrin subclass specificity. The differences among the 
structures of the A- and B-class molecules result in different architectural 
arrangements of receptor-ligand complexes, which probably maintained Eph 
receptor subclass specificity (Himanen et al., 2009). Upon complex formation 
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with ephrinB2, several notable structural variations are observed in EphA4. The 
B-class Eph-ephrin complexes have also been reported for significant structural 
rearrangements when binding to their ephrin ligands. In contrast, only minor 
structural changes have been observed upon formation of EphA-ephrinA complex. 
With intimate interactions between the Eph receptor B-C region and the 
juxtaposing C, F and G ephrin strands, complexes of EphB-ephrinB adopt a more 
‘compact’ conformation, whereas with a smaller number of interactions in the 
same region, the A-class complex is more ‘open’ with a more intimate interaction 
network between ephrin G-H loop and D-E, J-K and G-H loops of Eph receptor 
(Himanen et al., 2009).  
Previous study suggest that the A-class Eph receptor/ephrin interactions better 
described by a ‘lock-and-key’-type binding mechanism based on the small 
conformational rearrangements upon ephrin ligand binding, in contrast to the 
‘induced fit’ mechanism defining the B-class molecules (Himanen et al., 2009). 
While a recent protein dynamics study of EphA4 receptor ligand binding domain 
done by crystallography, NMR and molecular dynamic (MD) simulation showed 
that, based on the previous EphA4 ligand binding domain structures as a unbound 
state or binding with different ligands solved by X-ray crystallography and NMR, 
two groups of EphA4 receptor ligand binding domains presenting open and closed 
state already exist before binding to different ligands in crystal or solution. A third 
theory, ‘conformational selection and population shift’, was suggested to explain 
the promiscuity and specificity of the EphA4 ligand-binding domain to bind with 
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multiple A- and B-class ephrin ligands and small molecules (Nussinov and Ma, 
2012; Qin et al., 2012).  
 
1.1.5 Inhibitor design for Eph receptors and ephrin ligands 
 As members of the largest RTK family, together with their ephrin ligands, 
Eph receptors form a cell communication system with important and wide spread 
roles in normal physiology and disease pathogenesis. Imbalance of Eph/ephrin 
function may therefore contribute to a variety of diseases, such as diabetes, tumor, 
spinal cord injury, abnormal blood clotting and bone remodeling diseases. For 
example, EphB4 is widely expressed in cancer cells and its increased abundance 
has been correlated with cancer progression (Kumar et al., 2007; Kumar et al., 
2009; Noren and Pasquale, 2007). The critical roles of Eph receptors in various 
physiological and pathological processes and their correlation to cancers and 
diseases have validated the Eph receptor as the promising targets for the 
development of anti-tumor and neuronal regeneration drugs (Fabes et al., 2007; 
Fabes et al., 2006; Fry and Vassilev, 2005; Goldshmit et al., 2004; Klein, 2004; 
Tang et al., 2007; Yamaguchi and Pasquale, 2004). Most of the Eph 
receptor/ephrin interactions involve the extended G–H ephrin loop interacting 
with the Eph receptor surface channel according to the previous structural 
information of Eph receptors and ephrin ligands. It has been reported that some 
peptides and small chemical compounds could bind to the Eph receptor channel as 
antagonists and block Eph receptor signaling by preventing ephrin binding to Eph 
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receptor (Chrencik et al., 2006b; Chrencik et al., 2007; Koolpe et al., 2005; 
Koolpe et al., 2002; Murai et al., 2003; Qin et al., 2008). Those peptides that target 
the high affinity ligand-binding site are sufficient to inhibit Eph receptor-ephrin 
binding although there are several binding interfaces existing on Eph receptors. 
Moreover, unlike the ephrin ligands which bind to Eph receptors in a highly 
promiscuous manner, a number of the peptides identified by phage display 
selectively bind to only one or a few of the Eph receptors (Chrencik et al., 2007; 
Koolpe et al., 2005; Murai et al., 2003). Two small molecules 
(2,5-dimethylpyrrolyl benzoic acid derivative and its isomeric compound), 
identified by a high throughput screening, are able to antagonize ephrin-induced 
effects in EphA4-expressing cells. By interacting with residues in the D–E and 
J–K loops, the antagonizing benzoic acid derivatives occupy a cavity in the 
tradition ephrin-binding channel of EphA receptor (Noberini et al., 2008; Qin et al., 
2008). 
Beside the antagonistic peptides and small molecules targeted to the 
traditional ephrin ligand binding domain of Eph receptors, the antibodies and 
soluble forms of Eph receptors and ephrins extracellular domains that modulate 
Eph-ephrin interactions have also been identified (Ireton and Chen, 2005; Noren 
and Pasquale, 2007; Pasquale, 2005; Wimmer-Kleikamp and Lackmann, 2005). 
Several small inhibitors of the Eph receptor kinase domain have also been 
reported. These inhibitors occupy the ATP-binding pocket of the receptors and are 
usually broad specificity inhibitors that target different families of tyrosine kinases 
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(Caligiuri et al., 2006; Karaman et al., 2008).  
 
1.1.6 Functions of EphA5 and EphA7 receptors 
As a member of the Eph receptor tyrosine kinase family, EphA5 receptor is 
wildly expressed in most tissues, and higher expression mainly occurs in the 
hippocampus, striatum, hypothalamus, and amygdale in the adult brain (Gerlai et 
al., 1999). One of the most important functions of the EphA5 receptor is to work 
as an axon guidance molecule during neural development. By acting as a repellent 
cue during the migratory process, EphA5 receptor and its ligands prevent axons 
from entering inappropriate territories, and restrict the cells to specific pathways. 
During neural development, Eph receptors and their ligands are expressed in the 
projecting and target sites, respectively (Castellani et al., 1998; Wilkinson, 2001). 
Depending on the cell type, the binding of EphA5 receptors with ligands 
expressing neurons results in different consequences at the cellular level. It has 
been demonstrated that this interaction causes inhibition of the neurite outgrowth 
of the hippocampal, striatal, retinal, and cortical neurons (Brownlee et al., 2000). 
At the circuit level, over expression of a truncated form of EphA5 receptor cause a 
miswiring of the hippocamposeptal pathway and corpus callosum connections in 
vivo (Yue et al., 2002). Taken together, EphA5 receptor and its ligands serve as 
repulsive axon guidance cues in the developing brain. Binding of EphA5 and the 
ligands inhibits the neurite outgrowth and triggers growth cone collapse in vitro. 
Furthermore, abnormal expression of these molecules results in the disruption of 
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axonal path finding and mid-line crossing in vivo (Hu et al., 2003).  
 EphA7 receptor also plays different functional roles in variety of signaling 
pathways. EphA7 is frequently silenced in gastric colon, prostate cancers (Dawson 
et al., 2007; Pasquale, 2010); somatic mutations affecting EphA7 have been 
reported in non-small cell lung cancer (Ding et al., 2008). Co-expression of an 
endogenously expressed truncated form of EphA7 suppresses tyrosine 
phosphorylation of the full-length EphA7 receptor and shifts the cellular response 
from repulsion to adhesion in vitro (Holmberg et al., 2000). A recent study showed 
that knockdown of EphA7 drives lymphoma development in a murine follicular 
lymphoma (FL) model. A soluble splice variant of EphA7 (EphA7
TR
) can interfere 
with full-length EphA2 and blocks oncogenic signals in lymphoma cells (Oricchio 
et al., 2011). This study proved that EphA7 receptor could act as a tumor 
suppressor in follicular lymphoma with immediate therapeutic potential.  
 
1.1.7 Nogo as an Inhibitor of Axon Regeneration in CNS 
 Among the myelin-associated inhibitors for CNS axon regeneration, Nogo, 
MAG, and Omagp, Nogo is the most widely studied myelin-associated inhibitor 
(Prinjha et al., 2000). Nogo (RTN4) belongs to the reticulon family of membrane 
proteins, which is a eukaryotic gene family with ubiquitous expression and 
distinctive topological features (Oertle et al., 2003). Three different isoforms of 
Nogo, Nogo-A, -B and –C, are generated by alternative promoter and/or splicing 
(Figure 1.1.2). These three isoforms express ubiquitously, with some tissue 
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specificity. Among the three isoforms, Nogo-A is the longest one with an 
N-terminus around 1016 residues; Nogo-B has a N-terminus that is identical to the 
first 200 residues of Nogo-A and Nogo-C has a very short N-terminus. All the 
three Nogo isoforms share a conserved C-terminal domain consisting of 188 
residues called the reticulon-homology domain (RHD), which is highly conserved 
within RTN protein members (Oertle et al., 2003). 
           
 
Figure 1.1.2: The domain organization and dissection of the human Nogo 
proteins (Brittis and Flanagan, 2001). 
 
 As a well-studied protein, two inhibitory domains of Nogo-A responsible for 
the neurite growth inhibiting have been identified. The first one is a unique 
N-terminal region, which do not exist in Nogo-B and –C (Oertle et al., 2003). The 
second one is an extracellular 66 amino acid loop (Nogo-66) shared by all the 
three Nogo isoforms (Prinjha et al., 2000). Nogo-66 contains the three helices and 
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can bind to the Nogo-66 receptor family (NgR) consisting in three 
glycophosphatidylinositol (GPI)-anchored receptors (NgR1, NgR2 and NgR3) 
(Fournier et al., 2001; Li et al., 2006; Li et al., 2004).  
Previous studies for Nogos showed that they are involved in a variety of 
functional processes including apoptosis, CNS neurite regeneration, neuron 
pathologies, vascular remodeling and so on. For example, the protein level of 
Nogo-A is correlated with the most common neurodegenerative disease, 
Alzheimer’s disease. Nogo-B was identified as an apoptosis-inducing gene (Li et 
al., 2001) and a regulator of vascular remodeling (Miao et al., 2006). Nogo-C 
expressed in HEK293 could induce cell apoptosis by inducing caspase-3 and p53 
activation through the JNK-c-Jun dependent pathway (Chen et al., 2006).  
Shared by the three isoforms, Nogo-66 is an important region with multiple 
functions, especially in inhibiting of human CNS axonal regeneration. In contrary 
to human CNS, CNS in fish is able to regenerate axons. Previous study showed 
that the Nogo-A-specific domain lost in fish, but also Nogo-66 was modified so 
that Nogo does not impair axon regeneration (Abdesselem et al., 2009; Diekmann 
et al., 2005; Schweigreiter, 2008). Experiments also show that Nogo-66 in 
Zebrafish is growth permissive for both Zebrafish and mouse neurons, while the 
Nogo-66 homolog in rat inhibits growth in both species, even the two homologs 
have 70% sequence similarity (Abdesselem et al., 2009). Previously, our lab 
rationally designed and solved the NMR structure of a soluble form of Nogo-66 in 
human, Nogo-54 (Li et al., 2008). Nogo-54 is buffer soluble, well structured and 
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able to mimic Nogo-66 in inhibiting neurite outgrowth. In my thesis, the structure 
of Nogo-54 derived from Medaka fish was studied and determined by CD and 
NMR experiments and compared with the human Nogo-54 to get some clues 
related to the functional differences. 
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1.2 Protein Structure Determination 
Protein is an essential functional component of life, which presents in all 
living organisms. Protein is made of amino acids arranged in a linear chain and the 
tertiary structure of a protein is very important in understanding its function, 
dynamics and enzymatic mechanism at the atomic level. Common experimental 
methods to study the protein tertiary structures include X-ray crystallography, 
Nuclear Magnetic Resonance (NMR) spectroscopy, and cyro-electron microscopy. 
Both X-ray crystallography and NMR spectroscopy can yield information at 
atomic resolution. 
 
1.2.1 Nuclear Magnetic Resonance (NMR) spectroscopy 
1.2.1.1 NMR Phenomenon 
Nuclear magnetic resonance (NMR) is a property that magnetic nuclei have 
when the nuclei of certain atoms are placed in a static magnetic field and exposed 
to a second oscillating magnetic field, which cause the nuclei to absorb energy and 
then radiate it back out. The nuclear spin property of the nuclei decides whether 
the nuclei can experience the NMR phenomenon. Nuclear spin (I) is the angular 
momentum quantum number, a fundamental property of a nucleus. Based on the 
spin number (I) of a nucleus, the nuclei can be divided into three groups. The first 




O for example, has even mass numbers and even 
atomic numbers. This group has no magnetic moment and thus is NMR inactive. 
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C), are NMR active, which can 
give simple and interpretable signals and are widely used in NMR. The third 




N), is NMR active while the NMR signals of these 
nuclei are broaden and very difficult to be detected. In the external magnetic field, 
the nucleus, which has spin number of 1/2, can orient parallel or antiparallel to it. 
There are slightly different energies between the two possible orientations, which 
spins can jump from one to the other and absorb or emit the energy difference in 
the form of electromagnetic radiation. The different numbers of parallel and 
antiparallel spins contributes to the NMR signal. NMR signal sensitivity is 
proportional to γ3, in which γ is gyromagnetic ratio (or magnetogyric ratio), 








H has the largest gyromagnetic ratio.  
 
1.2.1.2 Chemical shift 
 Chemical shift, which is caused by electric de-shielding effect, is one of the 
most basic parameters of NMR spectroscope. The nuclei have different resonance 
frequencies and appear in the spectrum at different positions within different 
chemical environment. This is due to a small magnetic field created by electrons 
circulating around the nucleus, which can shield the nucleus from the external 
field. Therefore, each nucleus with its unique chemical environment in an NMR 
spectrum gives rise to a unique resonance. Chemical shift is denoted as δ and 
described by following equation, where V represents the precession frequency and 
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Chemical shifts of the amino acids are used to identify individual residues of 
a protein in NMR spectrum (Wuthrich, 1986). By comparing the observed 
chemical shifts with random coil values of the amino acids, the secondary 
structure of the protein can be predicted (Figure 1.2.1) (Wishart et al., 1991). 
     
Figure 1.2.1: Chemical shift deviations of Cα and Cβ from random coil values 
and the correlation with secondary structures (Spera and Bax, 1991).  
 
1.2.1.3 J coupling 
J coupling is also known as spin-spin coupling or scalar coupling, which can 
be observed when the nuclei have different environments or different chemical 
shifts and the distances between them are less than or equal to three bond lengths 
(Simon and Sattler, 2004). There are two types of J couplings: the coupled nuclei 
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with the same magnetogyric ratio γ and different chemical shifts have 
homonuclear coupling, such as proton-proton coupling. The J coupling for 













C are heteronuclear coupling. The Karplus 
equation can be used to estimate the correlation between J coupling and dihedral 
angels:  
J(θ)=Acos2 θ+Bcos θ+C 
Where J is the 
3
J coupling constant and θ is the dihedral angle. Deviation of 3JNHHα 
values from random coil values can also provide valuable secondary structural 
information of protein similar to chemical shift deviation (Figure 1.2.2). β 
structures have larger coupling constant values (8 to 10 Hz) than α-helical 
structures (3 to 5 Hz) in folded proteins, while in unfolded proteins the coupling 
constants are average (6 to 7.5 Hz) (Dyson and Wright, 2004; Pardi et al., 1984). 
          
 
Figure 1.2.2: Correlation between J coupling and protein secondary structure 
(Pardi et al., 1984). 
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1.2.1.4 Nuclear Overhauser Effect (NOE) 
Nuclear Overhauser Effect (NOE) is defined as a dipolar cross-relaxation 
phenomenon between spins through space magnetization transfer. NOE is 
proportional to the inverse sixth power of the distance (NOE ~ 1/r
6
) between 
protons at short mixing time as a function of interproton distances. NOE can 
normally be detected if the distances of the nuclei are less than 5 Å, otherwise it is 
too small to be observed. 
  
Figure 1.2.3: NOE patterns associated with secondary structure (Wuthrich, 
1986). 
 
Due to the correlation with distances between nuclei, NOE can provide much 
information for the 3D structure determination of protein. Intra-residue and 
sequential NOEs are not only used for establishing connections among amino 
acids, but also used to reveal protein secondary structure through the observed 
NOE patterns (Figure 1.2.3). Moreover, protons which far away on protein 
sequence but close to each other when proteins are well-folded in space can be 
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correlated by long-range NOE signals, providing the information for the protein 
tertiary structure calculation and determination (Wuthrich, 1986). 
 
1.2.1.5 Relaxation 
 When apply a 90° plus to the equilibrium longitudinal magnetization, the 
z-magnetization disappears and the transverse magnetization is created. The 
system is in a non-equilibrium state. The xy magnetization may eventually return 
to the thermal equilibrium state along the z-axis. The duration of this process is 
called relaxation and T1 and T2 are the two parameters used to describe it. T1 is 
called the longitudinal (or spin-lattice) relaxation after which the z magnetization 
reappears. Transverse relaxation time T2 is also called spin-spin relaxation time, 
which is the decay constant for the magnetization perpendicular to the ambient 




N heteronuclear NOE (hetNOE) provides 
information about the magnetization transferred from 
1
H to a heteronucleus. The 
flexible residues of protein those undergo motion faster than the overall tumbling 
of the molecules (i.e. in the picosecond to nanosecond time scale) would have 
decreased NOE intensities relative to the average intensity observed for most of 
the residues. Thus, it is very convenient to find the flexible residues of the protein. 
For instance, both N- and C-terminal ends of the protein probably have decreased 
value of hetNOE. 
 
  24 
1.2.1.6 NMR Structure Determination 
 The determination of a protein structure by NMR can be carried out in five 
major steps (Figure 1.2.4).  
 
Figure 1.2.4: Strategy of structure determination by NMR. 
 
1.2.1.6.1 NMR Sample Preparation 
 For NMR structure study, the protein sample is usually prepared at a 
concentration of 500 μM to 1 mM, depends on the protein solubility and stability. 
Based on the protein size and the NMR experiments need to be done, the protein 






C. The experiment parameter like sample 
pH, ionic strength and temperature should be adjusted to optimize the protein 
behavior in solution. Usually the protein solution is around 0.5 ml with 6% to 10% 
D2O inside. 
 
NMR Structure Calculation, Refinement and Evaluation 
Collection of Structure Constraints 
NOE, scalar coupling, dipolar coupling etc. 
Sequential Resonance Assignment 
HSQC, HNCACB, CBCA(CO)NH etc. 
Recording and Processing of NMR Spectra 
Sample Preparation 
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1.2.1.6.2 Recording and Processing of NMR Spectra 
 A set of multidimensional NMR experiments was recorded using the prepared 
protein sample. The spectra raw data were processed using Fourier transformation 
to obtain frequency domain data for assignments. 
 
1.2.1.6.3 Sequential Resonance Assignment 
 Assignment is to associate the resonance in an NMR spectrum with a 
particular nucleus of a certain residue of the examined protein. The protein 
backbone atoms (NH, C, CO, CA and CB) can be assigned using several 2D and 
3D NMR spectra, HSQC, HNCACB, and CBCA(CO)NH for example. Based on 
the assigned backbone atoms of the protein, the side chain atoms of particular 
residues can also be assigned using certain NMR spectra (NOESY etc.). 
 
1.2.1.6.4 Collection of Structure Constraints 
 NMR spectra can give useful geometric conformational information for 
protein structure determination. By adding the structure constraints like 
NOE-derived distance restrains, scalar coupling constants, residual dipolar 
coupling, torsion angles and hydrogen bonds, the protein structure quality can be 
increased.  
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1.2.1.6.5 NMR Structure Calculation, Refinement and Evaluation 
 The software can calculate the protein structure according to the empirical 
data and the know amino acid sequence of the protein and satisfy the majority of 
the experimental derived constraints. Then the calculated structures would be 
optimized following the energy minimization rules. Finally, PROCHECK is used 
to evaluate the calculated NMR structure (Laskowski et al., 1993). To get the good 
quality structures, the constrains violations, root mean square deviation (RMSD) 
of the structure ensemble and the Ramachandran plot of the calculated structures 
should be at reasonable value/region.  
 
1.2.1.7 Unique Features of NMR 
Bloch and Purcell first detected the NMR phenomenon independently in 1946, 
and NMR spectroscopy was first used to determine the structure of small 
molecules in organic chemistry. Only after Wuthrich developed the 2D experiment 
in the early 1980s (Wuthrich, 1986), NMR was applied for protein structure 
determination. 
Nowadays, for determining the three dimensional structures of biological 
macromolecules, NMR has become a powerful technique the same as X-ray 
crystallography. Compared with X-ray crystallography, NMR is able to solve 
protein structures in solution. Based on different aims, the condition of protein 
solution such as salt concentration and pH can be adjusted and protein 
conformational changes can be traced. NMR is more suitable for proteins with low 
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stability or solubility, especially for proteins that are unable to be crystalized 
compared with X-ray crystallography. Furthermore, NMR is also used to study 
protein dynamics, protein folding and intermolecular protein interactions.  
 
1.2.2 X-ray Crystallography 
1.2.2.1 Introduction 
 X-ray crystallography is the major technology to determine the protein 
tertiary structure.  By using a beam of X-rays to strike a crystal and diffract into 
many specific directions, the arrangement of atoms within the crystal can be told. 
From the angles and intensities of these diffracted beams, the three-dimensional 
picture of electron densities within the crystal can be produced. Using these data, 
the tertiary structure of the protein can be calculated by software. 
Max Perutz and Sir John Cowdery Kendrew solved the first crystal structures 
of sperm whale myoglobin protein (Kendrew et al., 1958). So far, among 78477 
biological macromolecule structures in the Protein Data Bank (PDB) (access on 
January 2012), over 87% of the structures (68639 protein structures) were solved 
by X-ray crystallography (Table 1.2.1, Figure 1.2.5) (Berman et al., 2000) 
(http://www.pdb.org). X-ray crystallography has a big advantage on solving 
structures of arbitrarily large molecules, whereas solution-state NMR is restricted 
to relatively small ones (less than 70 kDa). 
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X-ray 64155 1335 3147 2 68639 
NMR 8071 967 185 7 9230 
Electron Microscopy 277 22 101 0 400 
Hybrid 42 3 2 1 48 
Other 138 4 5 13 160 
Total 72683 2331 3440 23 78477 
 
    




 Crystallization is the first step to use X-ray crystallography for protein 
structure determination. Crystallization of proteins includes three stages: 
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protein crystals are: the hanging drop vapor-diffusion, the sitting drop 
vapor-diffusion, and the dialysis and batch methods. These methods can screen 
numerous protein crystallization conditions. There are many factors that may 
affect protein crystallization, such as protein concentration, precipitant, salt, 
additives and pH. Therefore, to get the protein crystallized well, it is very 
important to optimize the crystallization conditions. After getting the protein 
crystal, some post-crystallization methods, such as dehydration and soaking may 
help to improve the crystal quality. 
 
1.2.2.3 X-ray Crystallography 
 To solve a protein structure by X-ray crystallography, a protein crystal should 
be well ordered. It should be a symmetrical macromolecular package of protein 
molecules and solvent molecules. The crystal symmetry, the unit cell parameters, 
the crystal orientation and the resolution limits information are important 
parameters for the protein crystals.  
Direct methods, multiple isomorphous replacement (MIR), multi-wavelength 
anomalous dispersion (MAD), single-wavelength anomalous dispersion (SAD) 
and molecular replacement (MR) are the methods used to solve the phase problem 
in macromolecular structure determination. Molecular replacement is the simplest 
and very useful method to solve the phase problem when the protein molecule has 
high sequence and structural similarity to an already solved protein structure: A 
patterson map would be computed from the already solved homologous protein 
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structure, which is considered as a fingerprint. This patterson map is then modified 
in the new crystal unit-cell according to means of rotation functions. By the 
support of a convincing correlation factor and a residual factor, a best fit can be 
achieved finally. All these methods only yield phase estimates for a limited set of 
reflections. Furthermore, to improve the accuracy of the phase and to get an 
interpretable electron density map, with the help of Fourier transformation, 
refinement of both reciprocal and real space is carried out. 
The initial model generated with the MR method is usually not optimal. 
Refinement is needed to improve the model. Refinement of a model is the 
optimization of a function of a set of observations so that the correlation between 
the atomic model and the diffraction data is maximized. During the refinement, 
R-factor and Rfree-factor are monitored, which reflect the data quality. R-factor 
(also refers to ‘reliability’) is the agreement index between the refined structural 
models and experimentally observed X-ray diffraction data. Rfree-factor is the 
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1.3 Research Aims 
Eph receptors and Nogos play very important roles in the growth of neuron 
and many signal pathways as mentioned above. To illustrate the mechanism and 
interaction details of how they function in real life, three dimensional protein 
structures and dynamics of them invested by X-ray crystallography and NMR are 
very essential. Furthermore, some peptides and small compounds have been 
studied as inhibitors, which can inhibit interactions of Eph receptors and their 
ephrin ligands. These studies provide the possibility to treat Eph receptors and 
Nogos as therapeutic targets for central nerve system diseases, especially for 
anti-tumor and neuronal regeneration drug development, concerning the functional 
importance. 
Research aims of this study focus on three proteins. 
(1) For EphA5 and EphA7 receptor ligand-binding domains:  
Crystallize the EphA5/7 ligand-binding domains and resolve the 3D structures 
by X-ray crystallography. NMR spectroscopy was used to study their dynamic 
properties as unbound state. For EphA5, dynamic properties of its bound state 
with peptide/compound were studied. The binding abilities of EphA5 
ligand-binding domain with peptides or small compounds have been investigated 
by different methods. Their binding interfaces have been mapped out and 
compared by computer docking.  
(2) For Nogo-54: 
The 3D structure of Nogo-54 in Medaka fish has been investigated by NMR 
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spectroscopy. Human central nervous system does not have the ability to 
regenerate new axons compare to fish. Thus the 3D structure of fish Nogo-54 was 
subsequently compared with the NMR structure of the human Nogo-54.  
 
  










CHAPTER II. Material and Method  
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Chapter II. Material and Method 
2.1 Cloning. 
The DNA fragment of the human EphA5 ligand-binding domain (residues 
59–235) was amplified from a HeLa cell cDNA library using two primers 
containing BamHI and XhoI (New England Biolab) restriction sites, 5’- GGA 
TCC AAC GAA GTG AAT TTA TTG GAT TCA CGC -3’ (forward) and 5’- CTC 
GAG TCA AGA AGG CGC TTC TTT ATA GTA TAC -3’ (reverse). The PCR 
fragments were cloned into a BamHI and XhoI cut pET32a vector (Novagen), and 
then was transformed into E. coli DH5α cells (Novagen) for colony screening. 
Plasmids were amplified in E. coli DH5α cells and purified by QIAprep Spin 
Miniprep Kit (Qiagen). The free Cysteine 233 in this construct was mutated to 
Alanine by use of the site-directed mutagenesis kit (Stratagene) to avoid the 
formation of non-native disulfide bridges. All the performances were followed the 
protocols provided by the manufacturers. The procedures were monitored by 
Agarose DNA electrophoresis (Bio-Rad). Before expression of the recombinant 
proteins, the DNA sequences were confirmed by automated DNA sequencing.  
The DNA fragment of the human EphA7 ligand-binding domain with Sushi 
domain (EphA7L, residues 31–283) was also amplified from a HeLa cell cDNA 
library using two primers containing BamHI and XhoI (New England Biolab) 
restriction sites, 5’- CG GGA TCC AAG GAA GTA CTA CTG CTG -3’ (forward) 
and 5’- GGG CTC GAG TCA GAA CCC ACG GCC CGC GGG TTC ACA AGT 
GTC -3’ (reverse). The PCR fragments were cloned into a BamHI and XhoI cut 
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pET32a vector (Novagen), and then was transformed into E. coli DH5α cells 
(Novagen) for colony screening. Plasmids were amplified in E. coli DH5α cells 
and purified by QIAprep Spin Miniprep Kit (Qiagen). The free Cysteine 279 in 
this construct was mutated to Alanine to avoid the formation of non-native 
disulfide bridges. All the performances were followed the protocols provided by 
the manufacturers. The procedures were monitored by Agarose DNA 
electrophoresis (Bio-Rad). The DNA sequences were confirmed by automated 
DNA sequencing. 
PCR-based strategy was utilized to synthesize the genes encoding WDC 
peptide (peptide sequence: WDCNGPYCHWLG) and WTF peptide (peptide 
sequence: WTFPVLWDDKHP) (Wei and Song, 2005). Briefly, the gene encoding 
WDC was obtained by PCR with two long oligonucleotides: Forward Primer (5’- 
GGA TCC TGG GAT TGC AAC GGC CCG TAT TGC CAT TG- 3’) and Reverse 
Primer (5’- CTC GAG TCA GCC CAG CCA ATG GCA ATA CGG GCC -3’) with 
a 17-mer overlap designed with E. coli preferred codons containing BamHI and 
XhoI restriction sites. The gene encoding WTF peptide was obtained by PCR with 
two long oligonucleotides: Forward Primer (5’- TGG ACC TTT CCG GTG CTG 
TGG GAT GAT -3’) and Reverse Primer (5’- CGG ATG TTT ATC ATC CCA 
CAG CAC CGG -3’) with a overlap designed with E. coli preferred codons 
containing BamHI and XhoI restriction sites. The PCR fragment was cloned into a 
BamHI and XhoI cut pGEX-4T-1 vector (Amersham Biosciences), and the vector 
was transformed into E. coli DH5α cells (Novagen). 
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2.2 Preparation of Competent E. coli Cells. 
Competent cell (DH5α, BL21 or Rosetta-gami) grew on LB (Bio Basic Inc.) 
plate without ampicillin at 37°C overnight. Single bacterial colony was picked 
into 2 ml LB media with necessary antibiotics, grow overnight at 37°C while 
shaking at 200 rpm. Overnight culture was diluted into 100 ml fresh LB broth at a 
ratio of 1:100. Cells were grown at 37°C (200 rpm) till OD600 reached 0.4~0.5. 
The bacterial cells were transferred to sterile, disposable, ice-cold 50 ml 
polypropylene tubes and stored on ice for 10 minutes to reach 0°C. The cells were 
spun down at 3000*g for 10 minutes at 4°C. The cell pellet was then gently 
resuspended by swirling or gentle vortexing in 30 ml of ice-cold, sterile, fresh 
MgCl2-CaCl2 solution (80 mM MgCl2, 20 mM CaCl2). The cells were then 
recovered by centrifuged at 3000*g for 10 minutes at 4°C. After discarding the 
supernatant, cell pellet was resuspended by swirling or gentle vortexing in 2 ml of 
ice-cold 0.1 M CaCl2 with 15% glycerol (BDH Laboratory Supplies) for each 50 
ml of original culture. Cell resuspension was distributed in aliquots into 1.5 ml 
sterile eppendorf tubes. Competent cells were quick frozen by liquid nitrogen and 
then stored at -80°C for long time storage.  
 
2.3 Transformation of E. coli Cells 
1 or 2 μl plasmid DNA (about 100 ng/μl) was added into 100 μl of E. coli 
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competent cells and mixed well by gently tapping. The cells were incubated on ice 
for around 30 minutes, followed by a heat shock for 50 seconds and a subsequent 
incubation on ice for 2 minutes. 500μl of LB medium was added into the tube and 
incubated at 37°C for 60 minutes before plating cells onto LB Agar plates 
containing ampicillin.  
 
2.4 Protein Expression and Purification  
2.4.1 Expression and Purification of the EphA LBD 
The recombinant his-tag proteins of EphA receptor ligand-binding domains 
(EphA5/EphA6/EphA7) and EphA7 ligand-binding domain with sushi domain 
(EphA7L) were over expressed in E. coli Rosetta-gami (DE3) cells (Novagen) 
allowing more efficient formation of disulfide bonds and expression of eukaryotic 
proteins, which contain codons rarely used by E. coli. The cells were cultured in 
Luria-Bertani (LB) medium at 37°C while shaking at 200 rpm until the 
absorbance at 600 nm reached around 0.6. Then Isopropyl 
1-thio-D-galactopyranoside (IPTG) was added into the cell culture to a final 
concentration of 0.1 mM (for EphA5 and EphA7L) or 0.4mM (for EphA6 and 
EphA7) to induce protein expression at 18°C (for EphA5 and EphA7L) or 20°C 
(for EphA6 and EphA7) for overnight culture. The harvested cells were sonicated 
in the PBS lysis buffer containing 20 mM sodium phosphate (pH 7.5) and 150 
mM sodium chloride to release soluble his-tagged EphA proteins. Then the 
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recombinant proteins were subsequently purified by affinity chromatography 
using nickel-nitrilotriacetic acid-agarose (Qiagen) under native condition. EphA 
proteins were cleaved using in-gel cleavage at room temperature by incubating the 
fusion protein attached to nickel-nitrilotriacetic acid-agarose with thrombin 
overnight. The released EphA proteins were then purified on an AKTA FPLC 
machine (Amersham Biosciences) using a gel filtration column (HiLoad 16/60 
Superdex 75) equilibrated in 20 mM sodium phosphate containing 150 mM 
sodium chloride, pH7.5. 
For the crystallization of EphA5/EphA6/EphA7, the harvested cells were 
sonicated in 25 mM Tris-HCl (pH 7.8), containing 150 mM NaCl and 5 mM 
CaCl2. EphA proteins were then purified by in-gel cleavage and gel filtration in 
the same Tris buffer using nickel beads and gel filtration column Superdex 75. To 
increase the purity of the samples, the eluted fractions from gel filtration step were 
then buffer exchanged to 25 mM Tris-HCl (pH 7.8) containing 150 mM NaCl, and 
then purified by ion-exchange chromatography using anion-exchange column 
(Mono Q 10/100) with a gradient of NaCl from 0 to 1 M in 25 mM Tris-HCl (pH 
7.8). The eluted fractions which contained the EphA ligand-binding domains were 
collected and again dialyzed to 25 mM Tris-HCl buffer (pH 7.8), containing 150 
mM NaCl and 5 mM CaCl2 and stored at 4°C. The purity of the proteins was 
verified by the SDS-PAGE, and the identity of the samples was verified by 
MALDI-TOF mass spectrometry. 
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2.4.2 Expression and Purification of WDC and WTF Peptides 
The recombinant GST-tag WDC peptide was overexpressed in E. coli 
Rosetta-gami (DE3) cells and the GST-tag WTF peptide was overexpressed in 
BL21 cells. The cells were cultured in Luria-Bertani medium at 37°C until the 
absorbance at 600 nm reached ~0.6. Isopropyl 1-thio-D-galactopyranoside was 
then added to a final concentration of 0.5 mM to induce peptides expression at 
20°C overnight. The harvested cells were sonicated in lysis buffer containing 20 
mM sodium phosphate (pH 7.5) and 150 mM sodium chloride to release soluble 
GST-tagged peptides, which were subsequently purified with 
glutathione-Sepharose (Amersham Biosciences). The peptides were released from 
the GST fusion proteins by in-gel thrombin cleavage at room temperature for 4 
hours, followed by HPLC purifications on a RP-18 column (Vydac). The 
formation of disulfide bridge of WDC was determined by both HPLC and 
MALDI-TOF mass spectrometry. The identity of the WTF sample was also 
verified by MALDI-TOF mass spectrometry. 
 
2.4.3 Expression and Purification of Nogo-54 
 The recombinant his-tag Nogo-54 protein was expressed in the bacterial strain 
BL21. The cells were cultured at 37°C to an OD600 of around 0.6. IPTG was then 
added at a final concentration of 0.3 mM to induce the recombinant protein 
expression at 20°C overnight. Then the Nogo-54 protein was purified by 
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Ni
2+
-affinity chromatography under native conditions and subsequently purified 
by HPLC on a reverse-phase C8 column (Vydac). 
 
2.5 Preparation of Isotope Labeled Proteins 
The generation of the isotope-labeled protein for heteronuclear NMR 
experiments followed the similar expression and purification procedures except 
that the E. coli cells were grown in M9 medium (Na2HPO4•12H2O: 17.1 g/L (J. T. 
Baker); KH2PO4: 3 g/L (J. T. Baker); NaCl: 0.5 g/L; (NH4)2SO4: 1 g/L 
(Cambridge Isotope Laboratories Inc.); Glucose: 4 g/L (Sigma); MgSO4: 1 mM 
















2.6 Protein Analysis by SDS-PAGE 
 Hoefer Mighty small II electrophoresis unit (Amersham Pharmacia Biotech) 
was used to perform SDS-polyacrylamide gel electrophoresis. 5 μl of low range 
prestained SDS-PAGE standard (Bio-Rad) was used. After electrophoresis, 
SDS-PAGE was placed in staining solution (0.025% Coomassie brilliant blue 
R250; 40% methanol, 7% acetic acid) for about 10 minutes with gentle shaking. 
The gel was then destained using destaining solution.  
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2.7 Determination of Protein Concentration by Spectroscopy 
 The concentration of a protein solution is determined by measuring the 
absorbance of 280 nm (A) and using the Beer-Lambert Law: A= ε * l * C, where ε 




), l is the path length (cm), and C is the 
protein concentration (M). The absorption A of a protein at 280 nm depends on the 
content of Tryptophan, Tyrosine, and Cysteine (disulfide bonds), extinction 
efficient ε can be determined by following equation: 
ε(280)(M-1cm-1)=(#Try)(5500)+(#Tyr)(1490)+(#Cys)(125) 
#Try, #Tyr and #Cys are the numbers of each corresponding residue in a protein 
(Pace et al., 1995).  
8M Urea was added into the protein solutions to denature them, and then the 
solutions were measured by UV/visible spectrophotometer using 0.1 mm quartz 
cuvette at 280 nm. 
 
2.8 Circular Dichroism (CD) Measurement 
 A Jasco J-810 spectropolarimeter equipped with a thermal controller was used 
to perform the Circular Dichroism (CD) experiments of peptides and proteins. The 
far UV and near UV CD spectra of samples were recorded at 25°C in 10 mM 
phosphate buffer (pH 6.3) at a protein concentration of 10-50 μM using a 1 mm 
path length capped quartz cuvette (Liu et al., 2006) with a 0.1 nm spectral 
resolution. Data from three independent scans were added and averaged.  
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2.9 Protein Crystallization 
 For the X-ray crystallography experiments, to avoid the phosphate crystals, 
the buffer system changed from the phosphate buffer system to the Tris-HCl 
buffer system. The EphA receptor (EphA5/EphA6/EphA7) ligand binding 
domains were prepared in a buffer containing 25 mM Tris-HCl (pH 7.8), 150 mM 
NaCl and 5 mM CaCl2 at a concentration of 10 mg/ml. Crystal screen was set up 
by preparing 1 μl of the protein solution mixed with 1μl of the reservoir solution 
as hanging drops at room temperature in a well containing different reservoir 
solution. Rock-like crystals of EphA5 ligand binding domain formed in the well 
containing 0.1 M Tris-HCl (pH 8.5) and 2.0 M ammonium sulfate. After 
optimization, high quality crystals grew after 5 days under the condition of 0.1 M 
Tris-HCl (pH 8.5) and 2.0 M ammonium sulfate. 
 
2.10 Data Collection and Structure Determination 
 X-ray diffraction images for a single crystal were collected using an in-house 
Bruker X8 PROTEUM x-ray generator with a CCD detector. The crystal was 
protected by cryoprotectant (0.1 M Tris-HCl, 2.0 M ammonium sulfate, 25% 
glycol, pH 8.5). The data were indexed and scaled in the space group C2221, with 
one molecule per asymmetric unit, using the program HKL2000 (Otwinowski and 
Minor, 1997).  
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The crystal structure of EphA5 ligand binding domain was determined by the 
Molecular Replacement method using EphA4 ligand binding domain (Protein 
Data Bank code 3CKH) as a search module using Phaser and MolRep in the Suite 
CCP4. The crystal structure was subsequently completed by manual fitting with 
the program COOT (Emsley and Cowtan, 2004) and several rounds of structure 
refinements were done using CNS (Brunger et al., 1998). Water molecules were 
added into the model using CNS water-pick model. The final structure was 
analyzed by PROCHECK (Laskowski et al., 1993), and details of the data 
collection and refinement statistics are shown in chapter 3. All figures were 
prepared using the PyMOL molecular graphics system (W. L. DeLano, DeLano 
Scientific LLC, San Carlos, CA). 
 
2.11 Isothermal Titration Calorimetry (ITC) 
 All of the Isothermal Titration Calorimetry (ITC) experiments were 
performed using a Microcal VP ITC machine. Titration experiments were 
conducted in 10 mM phosphate buffer (pH 6.3) at 25°C. The samples were first 
degassed for 15 min and then centrifugation for 15 min to remove bubbles before 
experiments. The protein sample was placed in a 1.4 ml reaction cell while the 
peptides/ligands were loaded into a 300 μl injection syringe. Control experiments 
with the same parameter setting were also done to subtract the contribution of 
buffer or sample dilution. After subtracting the results of control experiments, ITC 
data were fitted by using the built-in software ORIGIN to yield the 
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thermodynamic binding parameters. 
 
2.12 HSQC Characterization of the Binding of EphA Receptors with Peptides and 
Ligands 
 To characterize the binding interactions of WDC/WTF peptides and the 





HSQC spectra of the 
15
N labeled EphA proteins were acquired at a protein 
concentration of ~100 μM in the absence or presence of WDC/WTF peptides or 
the compounds at different molar ratios. The shifted HSQC peaks were assigned 
by superimposing the HSQC spectra.  
 
2.13 NMR Backbone Assignment 




C double-labeled EphA5 ligand-binding domain with or 
without WDC was prepared in 10 mM phosphate buffer (pH 6.3) containing 0.02% 
(w/v) sodium azide and an addition of 10% D2O for NMR spin-lock. Two pairs of 
triple-resonance NMR spectra, HNCACB and CBCA(CO)NH were collected for 
the preliminary backbone sequential assignment at 25°C on an 800-MHz Bruker 
Avance spectrometer equipped with a shielded cryoprobe.  
0.5 mM double-labeled EphA7 ligand-binding domain was prepared in 10 
mM phosphate buffer (pH 6.3) containing 0.02% (w/v) sodium azide and an 
addition of 10% D2O for NMR spin-lock. A pair of triple-resonance NMR spectra, 
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HNCACB and (H)CC(CO)NH were collected for the preliminary backbone 
sequential assignment at 25°C on an 800-MHz Bruker Avance spectrometer 
equipped with a shielded cryoprobe. 
NMR data were processed with NMRPipe and analyzed with NMRView.  
 
2.14 NMR Structure Determination 
 A 0.8 mM solution of 
15
N-labeled nogo-54 protein sample was prepared in 
10mM phosphate buffer (pH 5.2) containing 0.02% (w/v) sodium azide with the 
addition of 10% D2O for the 
15
N-edited HSQC-TOCSY and HSQC-NOESY 
experiments. The NMR spectra were collected at 25°C on an 800-MHz Bruker 
Avance spectrometer equipped with a shielded cryoprobe. All NMR data were 
processed with NMRPipe and analyzed with NMRView.  
 For structural calculation, NOE were collected from NOESY spectra. A set of 
manually-assigned unambiguous NOE restrains together with dihedral angel 
restraints, which were predicted by TALOS program based on chemical shift 
values (Hα), were used to calculate initial structures of Nogo-54 by CYANA 
program (Guntert, 2004). More NOE cross-peaks in the NOESY spectra were 
added in the structure calculation with the availability of the initial structures. 
After many rounds of refinement, 10 lowest-energy structures were selected by 
CYANA program, and then were analyzed by the graphic software MolMol 
(Koradi et al., 1996). 
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2.15 NMR Relaxation Experiment 
 
15
N-labeled EphA5 protein samples with or without WDC/WTF peptides, 
ligands were prepared at a concentration of 0.8 mM in 10mM phosphate buffer 
(pH 6.3) containing 0.02% (w/v) sodium azide with the addition of 10% D2O for 
NMR spin-lock. 
15




N steadystate NOEs 
were determined at 25°C on an 800-MHz Bruker Avance spectrometer equipped 
with a shielded cryoprobe (Clore et al., 1990; Farrow et al., 1994; Kay et al., 
1989). 
15
N T1 values were measured from HSQC spectra recorded with relaxation 
delays of 10, 250, 650, 900, 1000, 1100 and 1300 msec. 
15
N T2 values were 





steadystate NOEs spectra were obtained when with and without 
1
H presaturation 
of duration 3 sec plus a relaxation delay of 5 sec at 800 MHz. 
 
2.16 Molecular Docking 
 The modules of the EphA receptor ligand-binding domains in complex with 
the antagonistic molecules were constructed by use of the HADDOCK software 
(de Vries et al., 2007; Dominguez et al., 2003) in combination with CNS (Brunger 
et al., 1998). They use the chemical shift perturbation data to derive the docking, 
while at the same time, allowing various degrees of flexibility. Three steps of the 
docking procedure were followed: first, randomization and rigid body energy 
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minimization; second, semi-flexible simulated annealing; and third, flexible 
explicit solvent refinement.  
 To conduct the docking, by using of the CNS protocol, hydrogen atoms were 
added to the structures. The online PRODRG server (Schuttelkopf and van Aalten, 
2004) was used to generate and energy-minimize the geometric coordinates and 
parameters for the small molecules.  
 Before the docking procedure, all the residues of EphA receptor 
ligand-binding domains with a chemical shift perturbation greater than the 
threshold value were set to be “active” residues, whereas according to 
HADDOCK definition, the neighbors of active residues were defined as “passive” 
residues. The residues located on the loop were set to be “fully flexible” residues 
during calculation. As a result, 1000 structures were generated for rigid body 
docking, and the best 100 ones out of all 1000 structures were chosen for 
semi-flexible simulated annealing and water refinement. Detailed analysis and 
display of three structures with the lowest energies are in next chapter.  
 
  










CHAPTER III. Results and Discussion 
 
  
  49 
CHAPTER III. Results and Discussion 
3.1 EphA5 Ligand-Binding Domain 
3.1.1 Expression and Purification of EphA5 LBD 
The recombinant his-tag protein of EphA5 ligand-binding domain was over 
expressed in E. coli Rosetta-gami (DE3) cells (Novagen) to get the correct 
formation of disulfide bonds. The harvested cells were sonicated in the PBS lysis 
buffer to release soluble His-tag EphA5 proteins. Then the recombinant proteins 
were subsequently purified under native condition and cleaved by in-gel cleavage 
at room temperature with thrombin overnight. The released EphA5 protein was 
purified on an AKTA FPLC machine using a gel filtration column. As assessed by 
FPLC size-exclusion chromatography, the EphA5 LBD is a monomer in solution 
(data not shown).  
For the crystallization of EphA5 LBD, the harvested cells were sonicated in 
Tris buffer. After purified by gel filtration column, to increase the purity of the 
EphA5, the eluted fractions from gel filtration step were then purified by 
ion-exchange chromatography. The whole expression and purification process of 
EphA5 ligand-binding domain and the purity of the purified protein were assessed 
by SDS-PAGE using 15% gel. His-tag has a molecular weight of ~2 kDa, EphA5 
LBD without His-tag is around 20 kDa, the identity of EphA5 was verified by 
MALDI-TOF mass spectrometry (data not shown). 
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3.1.2 Structural Characterization of EphA5 LBD by CD 
 The structural properties of EphA5 ligand-binding domain were fist 
investigated by far-UV CD spectroscopy. As shown in Figure 3.1.1A, the spectrum 
of EphA5 protein in 10mM phosphate buffer (pH 6.3) had a maximal negative 
peak at around 212 nm, which implied that EphA5 ligand-binding domain has a 
typical β-conformation. The near-UV CD spectra of EphA5 in the absence and 
presence of 8 M urea were also done to see the overall tertiary packing of EphA5 
LBD (Figure 3.1.1B). The near-UV spectra showed that without the 8 M urea, 
EphA5 adopted tight tertiary packing. While with 8M urea which is used to 
denature the protein sample, the property was lost under denatured condition. All 
the data were from three independent scans and were added and averaged. 
 
Figure 3.1.1: Preliminary structural characterization of EphA5 by CD. (A) 
Far-UV CD spectrum of 10 µM EphA5 in the 10 mM phosphate buffer (pH 6.3). 
(B) Near-UV CD spectra of EphA5 in 10 mM phosphate buffer (pH 6.3) without 
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3.1.3 Preliminary NMR Structural Characterization of EphA5 LBD 
 NMR HSQC experiment was used to further assess the structural properties of 
the EphA5 ligand-binding domain, which is a sensitive probe to both secondary 




N NMR HSQC 
spectra of EphA5 ligand binding domain showed a well-dispersed HSQC 
spectrum in both dimensions (~4 ppm over 
1
H and ~26 ppm over 
15
N dimensions), 
indicating that EphA5 protein had a well-packed tertiary structure as confirm by 
the CD spectra. Therefore, NMR experiments would be suitable for studying the 
structure of EphA5, binding affinity and dynamic characterizations of EphA5 
binding with peptides/ligands.  






N HSQC spectrum of the EphA5 ligand-binding domain 
collected in a phosphate buffer at pH 6.3. 
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3.1.4 Crystal Structure of EphA5 LBD  
The EphA5 ligand binding domain was prepared in a buffer containing 25 
mM Tris-HCl (pH 7.8), 150 mM NaCl and 5 mM CaCl2 at a concentration of 10 
mg/ml. Crystal screen was set up by preparing 1 μl of the protein solution mixed 
with 1μl of the reservoir solution as hanging drops at room temperature in a well 
containing the reservoir solution. Rock-like crystals formed in the well containing 
0.1 M Tris-HCl (pH 8.5) and 2.0 M ammonium sulfate after 5 days. 
 
3.1.4.1 Structure of EphA5 Ligand Binding Domain Determined from Crystal 
X-ray diffraction images for a single crystal were collected using an in-house 
Bruker X8 PROTEUM x-ray generator with a CCD detector. The crystal was 
protected by cryoprotectant (0.1 M Tris-HCl, 2.0 M ammonium sulfate, 25% 
glycol, pH 8.5). The data were indexed and scaled in the space group C2221 
(a=54.80, b=83.34, c=81.30), with one molecule per asymmetric unit, using the 
program HKL2000. The Matthews coefficient was 2.29 with 46.20% solvent 
constant. 
The crystal structure of EphA5 ligand binding domain was determined by the 
Molecular Replacement method using EphA4 ligand binding domain (Protein 
Data Bank code 3CKH) as a search module using Phaser and MolRep in the Suite 
CCP4. The crystal structure was subsequently completed by manual fitting with 
the program COOT and further refined with program suite Crystallography & 
NMR System (CNS) (Brunger et al., 1998) at 2.99 Å resolution with a final 
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R-factor of 0.2504 (Rfree=0.2940). Only one EphA5 molecule contained in one 
asymmetric unit, and there are no tight contacts with other EphA5 molecules in 
the neighboring units. The final structure was analyzed by PROCHECK, and 
details of the data collection and refinement statistics are shown in Table 3.1.1. All 
figures were prepared using the PyMOL molecular graphics system (W. L. 
DeLano, DeLano Scientific LLC, San Carlos, CA). 
From the 3D structure, all the residues of EphA5 ligand binding domain are 
visible except for the last three residues (Figure 3.1.3). The EphA5 ligand-binding 
domain adopts the conserved jellyroll folding architecture previous revealed for 
other Eph receptors. The jellyroll consists of 11 anti-parallel beta-sheets arranged 
as a compact beta-sandwich, which connected by loops of different length and two 
disulfide bonds. The concave sheet is composed of strands C, F, L, H and I and the 
convex sheet of strand D, E, A, M, G, K and J.  
 
Figure 3.1.3: Crystal Structure of the EphA5 Ligand Binding Domain. 
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Table 3.1.1: Crystallographic data and refinement statistics for the EphA5 
ligand-binding domain structure. 
 
 Data collection  
 Wavelength (Å) 1.5418 
 Resolution range (Å) 50.0 to 2.9 
 Space group C222(1) 
 Cell parameters  
 a, b, c (Å) 54.80, 83.34, 81.30, 
 α, β, γ (°) 90, 90, 90 
 Observed Reflections 8975 
 Unique Reflections 3682 
 Redundancy 4.0 
 Completeness (%) 97.67% 
 Overall (I/σI) 19.12 
 Rsym 0.288 
 Refinement  
 Resolution range (Å) 24.78 to 2.99 
 Rwork* 0.2504 
 No. of reflections 3429 
 Rfree** 0.2940 
 No. of reflections 253 
 RMSD bond lengths (Å) 0.019 
 RMSD bond angles (°) 2.117 
 Ramachandran Plot  
 Most favored region (%) 74.8 
 Additional allowed regions (%) 24.5 
 Generously allowed regions (%) 0 
 Disallowed regions (%) 0.6 
 B-factors  
 Protein 3.751 
 Water 3.925 
 
*Rwork= Σ |Fobs - Fcalc|/ ΣFobs where Fcalc and Fobs are the calculated and observed 
structure factor amplitudes, respectively. 
**Rfree=as for Rwork, but for 10.3% of the total reflections chosen at random and 
omitted from refinement. 
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3.1.4.2 Comparison of EphA5 LBD Structure with Previous Eph LBD Structures 
 As seen in Figure 3.1.4, EphA5 LBD has two conserved disulfide bridges, one 









). This pattern of disulfide bonds is identical to that observed 
previously in other EphA and EphB receptor ligand binding domains (Chrencik et 
al., 2006a; Chrencik et al., 2006b; Chrencik et al., 2007; Himanen et al., 2004; 
Himanen et al., 2009; Himanen et al., 1998; Himanen et al., 2001; Qin et al., 
2008).  
 
Figure 3.1.4: Stereo view of the two disulfide bridges in the EphA5 ligand 
binding domain built into the simulated-annealing 2Fo-Fc electron density 
map contoured at 1.6σ.  
 
 The D-E and J-K loops, which cap the high affinity ephrin-binding pocket, are 
well defined in the crystal structure, while the quality of electronic densities is not 
high due to the low resolution (Figure 3.1.5). This is unique because in most 
previously determined unbound Eph receptor LBD structures, the D-E and J-K 
loops were either entirely or partially invisible due to their high intrinsic dynamics. 
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The only exception is the EphA2 LBD structure (Figure 2A), which was 
determined at a higher resolution (2.0 Å). 
   
Figure 3.1.5: Electron density map of the D-E and J-K loops in the EphA5 
ligand binding domain built into the simulated-annealing 2Fo-Fc electron 
density map contoured at 1.6σ. 
 
EphA5 was compared with other previously determined Eph receptor ligand 
binding domain structures both in the unbound state and in the bound state of their 
ephrin ligands (Figure 3.1.6). The structure of EphA5 ligand binding domain bears 
a highly similar jellyroll folding architecture composed of eleven antiparallel 
beta-stands to the previously determined ligand binding domains of the EphA2, 
EphA4, EphB2 and EphB4 receptor. The backbone r.m.s.d. of the EphA5 
ligand-binding domain over 11 beta-strands are quite small compared with the 
previous solved Eph receptor structures. On the other hand, over the loop region, 
very large variations could be observed not only between EphA5 and the EphB 
receptors but also between Eph receptors from the same A- or B-subclasses, in 
particular over the D-E and J-K loops, which are critical for ligand binding. A 
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recent protein dynamics study of EphA4 receptor ligand binding domain done by 
crystallography, NMR and molecular dynamic (MD) simulation showed that, 
based on the previous EphA4 ligand binding domain structures as a free state or 
binding with different ligands solved by X-ray crystallography and NMR, two 
groups of EphA4 receptor ligand binding domain presenting open and closed state 
already exist before binding to the different ligands in crystal or solution. 
Compared with the EphA4 LBD in the open form that has a 310-helix in the J-K 
loop, the EphA4 LBD in the closed form adopted an additional short beta-sheet. 
Interestingly, the J-K loop in the unbound EphA5 LBD appears more similar to 
the J-K loops in the ephrin-bound structures of other Eph receptors (Figure 3.1.6B) 
than in the unbound structures (Figure 3.1.6A). The J-K loops in the unbound Eph 
receptor LBD structures previously reported contain a short antiparallel beta-sheet, 
as exemplified in the EphB2 and EphA4 structures (Figure 3.1.6A). In contrast, 
the J-K loop adopts a helical-like conformation in the unbound EphA5 LBD 
crystal structure, similar to that observed only in ephrin-bound Eph receptor LBDs 
(Figure 3.1.6B). This observation suggests that EphA5 molecule may go through 
the small conformational rearrangements upon ephrin ligand binding, which is 
similar to the previous studied A-class Eph receptor/ephrin interaction described 
by a ‘lock-and-key’-type binding mechanism, in contrast to the ‘induced fit’ 
mechanism defining the B-class molecules (Himanen et al., 2009). 
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Figure 3.1.6: Structure comparison. (a) Superimposition of the LBD structure of 
EphA5 (red) with those of EphA2 (green, 3C8X), EphA4 (yellow, 3CKH) and 
EphB2 (blue, 3ETP) in the unbound state. It is interesting to note that a short 
β-sheet is formed by EphA2, EphA4 and EphB2 residues corresponding to EphA5 
residues Ala179-Ser182 and Gly189-M193 (brown arrows). (b) Superimposition 
of the LBD structure of EphA5 (red) with those of EphA2 in complex with 
ephrin-A2 (green, 3CZU), EphA4 in complex with ephrin-A2 (cyan, 3WO3), 
EphA4 in complex with ephrin-B2 (blue, 3GXU), EphB2 in complex with 
ephrin-B2 (pink, 1KGY) and EphB4 in complex with ephrin-B2 (yellow, 2HLE).   
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3.2 EphA5 LBD with Antagonistic Peptides 
 EphA5 receptor and its ligands serve as repulsive axon guidance cues in the 
developing brain. Their interaction triggers growth cone collapse and inhibits the 
neurite outgrowth in vitro. A number of peptides identified by phage display show 
their selectivity, high binding affinity with EphA5 receptor (Chrencik et al., 2006b; 
Chrencik et al., 2007; Koolpe et al., 2005; Koolpe et al., 2002; Murai et al., 2003; 
Qin et al., 2008). Those peptides that target the high affinity ligand-binding site 
are sufficient to inhibit Eph receptor-ephrin binding although there are several 
binding interfaces existing on Eph receptors. Moreover, unlike the ephrin ligands 
which bind to Eph receptors in a highly promiscuous manner, a number of the 
peptides identified by phage display selectively bind to only one or a few of the 
Eph receptors (Chrencik et al., 2007; Koolpe et al., 2005; Murai et al., 2003). To 
assess whether the purified EphA5 LBD retains the ligand binding properties 
expected for the EphA5 receptor, we measured its binding to the WDC 
(WDCNGPYCHWLG) and WTF (WTFPVLWDDKHP) peptides. These peptides 
were previously identified in a phage-display screen based on its binding to the 
entire extracellular domain of rat EphA5 (Murai et al., 2003). 
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3.2.1 Characterization of Binding Interactions between EphA5 LBD and 
WDC/WTF Peptides by NMR and ITC 
As shown in Figure 3.2.1, the NMR titration and ITC experiments were 
performed to analyze the binding affinity between EphA5 ligand binding domain 
and WDC/WTF peptides.  
From Figure 3.2.1 B, C and Table 3.2.1 of ITC experiments; the Kd for the 
binding of EphA5 with WDC was 6.22 μM, demonstrating that the WDC peptide 
binds to the LBD of human EphA5, and not other domains in the extracellular 
region. Consistent with this, in ELISA assays the WDC peptide antagonizes 
EphA5-ephrin-A5 interaction with an IC50 value of around 50 μM (data not 
shown). The synthetic WDC peptide inhibits ephrin binding to EphA5 and not 
other Eph receptors, with the possible exception of a slight inhibition of EphA6, 
consistent with the high selectivity of the phage-displayed peptide (Murai et al., 
2003). These results suggest that the WDC peptide binds to the high affinity 
ephrin-binding pocket of EphA5, where it competes with ephrins for binding. 
Moreover, the high selectivity of WDC implies that the high affinity ephrin 
binding pocket of EphA5 has some unique structural or/and dynamic properties 
that are not shared by other Eph receptors.  
For binding between EphA5 ligand binding domain and WDC peptide, the 
NMR spectra showed that the HSQC peak set from the free 
15
N-labeled EphA5 all 
shifted to become identical compared to the set from the complex of EphA5 and 
WDC when the molar ratio of EphA5 to WDC reached 1:3 (Figure 3.2.1A). This 
  61 
is consistent with its low micromolar affinity as the KYL peptide is also capable 
of inducing extensive shifting of the HSQC peaks of the EphA4 LBD, with a Kd of 
0.8 μM (Lamberto et al., 2012). 
For binding between EphA5 ligand binding domain and WTF peptide, dislike 
the binding between EphA5 ligand binding domain and WDC peptide, NMR 
spectra showed that many HSQC peaks from the free 
15
N-labeled EphA5 
disappeared in the presence of WTF peptide, when the molar ratio of EphA5 to 
WTF reached 1:1 (Figure not shown). More peaks have disappeared when the 
molar ratio of EphA5 to WTF reached 1:3 (Figure 3.2.2A). When the molar ratio 
of EphA5 to WTF reached 1:4, the HSQC peaks showed no significant differences, 
indicating that the binding of EphA5 and WTF had become saturated. From 
Figure 3.2.2 B, C and Table 3.2.1 of ITC experiments, the Kd for the binding of 
EphA5 with WTF was 8.69 μM, which indicated the binding between EphA5 and 
WTF is a litter weaker than the binding between EphA5 and WDC. 
 We also probed the uniqueness of the EphA5 ligand-binding pocket by using 
C1, an antagonistic small molecule that shows selectivity for the EphA2 and 
EphA4 receptors and has been shown to cause shifts in the HSQC peaks of the 
EphA4 LBD (Noberini et al., 2011; Qin et al., 2008). Consistent with the reported 
selectivity of C1 for EphA2 and EphA4 (Noberini et al., 2008), addition of C1 at 
ratios of even up to 1:20 (EphA5: C1) resulted in no detectable shifts of the HSQC 
peaks (data not shown). This clearly demonstrates that the EphA5 LBD does not 
significantly bind to C1, suggesting that the unique structural features of the J-K 
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loop in the EphA5 LBD crystal structure may play a key role in defining its ligand 




Figure 3.2.1: NMR and ITC characterization of the binding between EphA5 
and WDC. (A) Superimposition of the HSQC spectra of the 
15
N-labeled EphA5 in 
the absence (blue) and presence (red) of WDC at a molar ratio of 1:3. (B) ITC 
titration profiles of the binding reaction between EphA5 and WDC. (C) Integrated 
values for reaction heat with subtraction of the corresponding blank results 
normalized by the amount of ligand injected versus WDC/EphA5 molar ratio. The 
detailed conditions and setting of the ITC experiments are presented in Materials 










Figure 3.2.2: NMR and ITC characterization of the binding between EphA5 
and WTF. (A) Superimposition of the HSQC spectra of the 
15
N-labeled EphA5 in 
the absence (blue) and presence (red) of WTF at a molar ratio of 1:3. (B) ITC 
titration profiles of the binding reaction between EphA5 and WTF. (C) Integrated 
values for reaction heat with subtraction of the corresponding blank results 
normalized by the amount of ligand injected versus WTF/EphA5 molar ratio. The 
detailed conditions and setting of the ITC experiments are presented in Materials 
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Table 3.2.1: Thermodynamic parameters of the binding interactions between 














































3.2.2 Mapping of Binding Interfaces between EphA5 and WDC/WTF 
 WDC/WTF peptides could bind with EphA5 receptor with high affinity. The 
interface between EphA5 ligand binding domain and WDC/WTF peptides was an 
interesting target to be studied by NMR spectroscopy. A series of 
three-dimensional heteronuclear NMR experiments were done for mapping the 
binding interface between EphA5 and WDC/WTF peptides. 
 
3.2.2.1 Backbone Sequential Assignments of EphA5 LBD in the Presence and 
Absence of WDC Peptide 
 Two pair of triple-resonance NMR spectra, HNCACB and CBCA(CO)NH 




C double-labeled EphA5 protein sample without/with 
the addition of WDC peptide (the molar ratio of WDC to EphA5 is 1:3) to obtain 
the preliminary backbone sequential assignment for EphA5, respectively. Figure 
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3.2.3 and Figure 3.2.4 showed the HSQC spectra of assigned EphA5 backbone 
peaks in the absence and presence of WDC peptide, respectively.  
 Previous study of NMR show that the chemical shift deviation of Cα, Cβ, Hα, 
and C=O from random coil value reflects the secondary structure of protein 
(Wishart and Sykes, 1994). After finishing all the chemical shift assignment, 
secondary structures of free EphA5 ligand binding domain and EphA5 protein 
binding with WDC peptide were calculated by both Cα and Cβ chemical shifts to 
evaluate the conformational changes of EphA5 ligand binding domain induced by 
binding with WDC peptide. Figure 3.2.5 and Figure 3.2.6 show that the secondary 
structures calculated by Cα and Cβ were consistent with the EphA5 crystal 
structure obtained by X-ray crystallography. Meanwhile, compare the secondary 
structures calculated for free EphA5 and EphA5 binding with WDC (Figure 3.2.5 
and Figure 3.2.6), the binding of WDC to EphA5 did not induce significant 
conformational changes to the secondary structure of EphA5 ligand binding 
domain. 
  








N HSQC spectrum of the EphA5 ligand-binding 
domain in the absence of WDC peptide. 
 
  








N HSQC spectrum of the EphA5 ligand-binding 
domain in the presence of 3-fold WDC peptide. 
 
  





Figure 3.2.5: EphA5 LBD chemical shift deviation of Cα from random coil 
value provides insights in its secondary structure. Cα conformational shifts 
deviation of EphA5 LBD from random coil value (Cα0) in the presence (blue) and 
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Figure 3.2.6: EphA5 LBD chemical shift deviation of Cβ from random coil 
value provides insights in its secondary structure. Cβ conformational shifts 
deviation of EphA5 LBD from random coil value (Cβ0) in the presence (blue) and 
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3.2.2.2 Mapping of Binding Interface between EphA5 and WDC by Chemical Shift 
Perturbation Analysis 
 Because the chemical shift value of an NMR active atom is sensitive to its 
chemical environment, chemical shift perturbation analysis upon titration of 
ligands represents a powerful method for identifying residues that directly contact 
the ligands or that are indirectly affected by the binding event (Qin et al., 2008). 
 As shown in Figure 3.2.1A, most of the HSQC peaks of the free 
15
N-labeled 
EphA5 shifted to become identical with the HSQC peaks of the complex of 
EphA5 and WDC spectrum when the molar ratio of EphA5 to WDC reached 1:3. 
When the molar ratio of EphA5 to WDC reached 1:4, the HSQC peaks showed no 
significant shift, indicating that the binding of EphA5 and WDC had become 
saturated. Therefore, the chemical shift differences (CSD) between the free EphA5 
state and the complex state (the molar ratio of EphA5 to WDC was 1:3) could be 
calculated according to the formula ((Δ1H)2 + (Δ15N)2/5)1/2, and the results were 
plotted against EphA5 sequence as shown in Figure 3.2.7.  
 From the results, thirteen residues of EphA5 that gave shifted resonance peaks 
were found with significant CSD (peaks of EphA5 with CSD value larger than 1.0 
ppm). Residues of I28, G29 and V31 were located on the D β-strand, E33 was 
located on the D-E loop, T40 and V43 were located on the E β-strand, T75 on the 
G β-strand, D122, E127, R133 and K136 were on the J-K loop, N138 on the K 
β-strand and A164 was located on the M β-strand (Figure 3.2.8).  
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 Previous research showed that D-E and J-K loops are the key component of 
the high affinity ephrin binding pocket of the Eph receptors (Himanen et al., 2009; 
Qin et al., 2008). In this chemical shift perturbation analysis, most of the residues 
with significant chemical shift differences (CSD) values were located inside the 
traditional binding pocket surrounded by D-E and J-K loops or on the D-E and 
J-K loops. Therefore, the NMR titration results suggested that WDC peptide 
probably bind to the highly conserved high affinity ephrin-binding pocket of 
EphA5 ligand binding domain with high binding affinity.  
 
 
Figure 3.2.7: Residue-specific chemical shift differences (CSD) of the EphA5 
ligand-binding domain in the presence of 3-fold WDC. Red bars indicate 
residues of EphA5 ligand-binding domain with CSD larger than 1.0 ppm. 
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Figure 3.2.8: EphA5 ligand binding domain crystal structure with red color 
indicating residues of EphA5 with CSD larger than 1.0 ppm after binding 
with WDC peptide. 
 
3.2.2.3 Mapping of Binding Interface between EphA5 and WTF Peptide 
 Figure 3.2.2A shows that dislike the binding between EphA5 ligand binding 
domain and WDC peptide, many HSQC peaks from the free 
15
N-labeled EphA5 
disappeared in the presence of WTF peptide, when the molar ratio of EphA5 to 
WTF is 1:3. Therefore, disappeared and shifted peaks were identified on the 
crystal structure of EphA5 ligand binding domain according to the NMR titration 
results, to show the active residues involved in the binding interaction of EphA5 
and WTF peptide (data not shown). From the results, the HSQC peaks of 32 out of 
177 residues of EphA5 ligand binding domain disappeared and two shifted when 
compare the spectra of free EphA5 and the molar ratio of EphA5 to WTF equal to 
1:1; and the HSQC peaks of 26 residues of EphA5 ligand binding domain 
disappeared when compare the spectra of the molar ratio of EphA5 to WTF equal 
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to 1:1 and the molar ratio of EphA5 to WTF equal to 1:3. Most identified residues 
were located on the ephrin-binding channel, D-E loop, J-K loop, and G-H loop, 
indicating that WTF peptide binding with EphA5 ligand binding domain at the 
highly conserved ephrin-binding site. Interestingly, there are some identified 
residues located at the opposite site of ephrin-binding channel, suggesting that 
these residues may indirectly affected by the binding event due to the 
conformational changes when EphA5 LBD binds to WTF peptide.  
 
3.2.3 Molecular Docking for EphA5 LBD and WDC/WTF Peptides 
 The structure of EphA5 ligand binding domain and the two antagonistic 
peptides could not be calculated with NMR distance constraints due to the absence 
of intermolecular NOEs between them. As an alternative, the modules of the EphA 
receptor ligand-binding domains in complex with the antagonistic molecules were 
constructed by use of the HADDOCK software (de Vries et al., 2007; Dominguez 
et al., 2003) in combination with CNS (Brunger et al., 1998). HADDOCK is a 
well-established docking procedure that makes use of the chemical shift 
perturbation data to drive the docking of protein-protein and protein-small 
molecule complexes, while at the same time, allowing various degrees of 
flexibility. 
 The x-ray structure of EphA5 ligand binding domain was used to build up the 
docking model. From the structures obtained from the computational docking, 
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complex structures with the lowest energies were selected for further display and 
analysis.  
 
3.2.3.1 Molecular Docking for EphA5 LBD in complex with WDC Peptide 
Attempts to co-crystalize EphA5 with WDC were not successful, so the 
modules of the EphA receptor ligand-binding domains in complex with GS-WDC 
were constructed by use of the HADDOCK software based on previous NMR 
titration results and CSD analysis. The solution accessible residues of the EphA5 
ephrin-binding domain with larger chemical shift perturbation values were set as 
active residues according to the Haddock definition. As shown in Figure 3.2.9, 
GS-WDC peptide binds to EphA5 within its traditional ephrin ligand-binding 
channel. The side chain amide protons of GS-WDC residues G1 bind to two side 
chain oxygen atoms of E30 and Q42 on EphA5 LBD. The side chain amide proton 
of EphA5 residue Q42 can also interact with the backbone oxygen of S2 on 
GS-WDC peptide. EphA5 residue G29 backbone oxygen formed one hydrogen 
bond with side chain amide proton of N6 on GS-WDC peptide, consistent with the 
large chemical shift perturbation value showed previously. Furthermore, side 
chain amide protons of H11 on GS-WDC formed two hydrogen bonds with E127 
and D129 on EphA5 separately. The last residue of GS-WDC, G14 also interacted 
with side chain amide proton of EphA5 residue R77. Hydrophobic WDC residues 
W3, W12 and L13 also contact with the hydrophobic patches of the 
ephrin-binding pocket of EphA5 (Figure 3.2.9B). 
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Figure 3.2.9: Models of EphA5 ligand binding domain in complex with WDC 
peptide. (A) Stereo view of the superimposition of the unbound EphA5 structure 
(red) with the selected docking model in complex with WDC peptide (blue). (B) 
Surface representation of the EphA5 ephrin-binding domain showing electrostatic 
potentials (blue: positive, red: negative, gray: neutral) and stick representation of 
the GS-WDC peptide (yellow). 
 
 
3.2.3.2 Molecular Docking for EphA5 LBD in complex with WTF Peptide 
Attempts to co-crystalize EphA5 with WTF were not successful, so the 
modules of the EphA receptor ligand-binding domains in complex with WTF were 
constructed by use of the HADDOCK software based on previous NMR titration 
results. As shown in Figure 3.2.10, WTF peptide also binds to EphA5 ligand 
binding domain within the traditional ephrin-binding pocket. Based on the 
docking result, hydrogen bonds forming between backbone oxygen atoms of WTF 
residue L6 and D9 with EphA5 residue G131 backbone amide proton on the J-K 
loop and S167 side chain proton separately. Side chain oxygen atoms of WDC 
residue D8 and D9 also interact with EphA5 residue R8 and K73 amide proton on 
(A) (B) 
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the side chain. The side chain amide protons of WTF residue K10 form two 
hydrogen bonds with two EphA5 residues on the D-E loop, D32 and E33. The 
side chain amide protons of WTF residue H11 also form two hydrogen bonds with 
the EphA5 residues D7 and E71. Hydrophobic WTF residues W1, F3, P4 and W7 
establish extensive contacts with the hydrophobic patches of the ephrin-binding 
pocket of EphA5 (Figure 3.2.10B). For example, W1 is involved in hydrophobic 
contacts with EphA5 residues M47, L82, P83 and L86. 
 
Figure 3.2.10: Docking models of EphA5 ligand binding domain in complex 
with WTF peptide. (A) Stereo view of the superimposition of the unbound 
EphA5 structure (red) with the selected docking model in complex with WTF 
peptide (blue). (B) Surface representation of the EphA5 ephrin-binding domain 
showing electrostatic potentials (blue: positive, red: negative, gray: neutral) and 
stick representation of the WTF peptide (yellow). 
  
(A) (B) 
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3.3 Interactions of EphA5 LBD with small molecules 
 As mentioned before, EphA5 receptor and its ligands play different roles in 
various physiological and pathological processes. Until now, not only the 
antagonistic peptides, but also some small molecules have been identified by high 
throughput screening to antagonize ephrin-induced effects by targeting Eph-ephrin 
binding pocket (Noberini et al., 2008). Besides these antagonistic small molecules, 
Doxazosin Mesylate (in short as Dox), a quinazoline compound that can 
selectively and competitively blocks postsynaptic alpha-1-adrenergic receptors 
and used for treatment of arterial hypertension and congestive heart failure, could 
bind to and active EphA2 and EphA4 as an agonist.  
 
              
Figure 3.3.1: The chemical structures of Doxazosin Mesylate.  
 
3.3.1 Characterization of Binding Interactions between EphA5 LBD and Doxazosin 
Mesylate by NMR and ITC 
The NMR titration and ITC experiments were performed to assess whether 
Doxazosin Mesylate molecule directly interacts with the EphA5 ligand-binding 
domain. For visible precipitations would form with adding the Doxazosin 
  78 
Mesylate solutions into the EphA5 ligand binding domain samples, we succeeded 
in obtaining these parameters of ITC experiments by using a low EphA5 ligand 
binding domain concentration (30 μM). The NMR and ITC experiments data are 
presented in Figure 3.3.2 and Table 3.3.1, that clearly confirming that Doxazosin 
Mesylate do interact with the ligand binding domain of EphA5.  
For binding between EphA5 ligand binding domain and Doxazosin Mesylate, 
the NMR spectra showed that some of the HSQC peaks of the complex of EphA5 
ligand binding domain and Doxazosin Mesylate shifted obviously compared to the 
free 
15
N-labeled EphA5 when the molar ratio of EphA5 to Doxazosin Mesylate 
reached 1:14 (Figure 3.3.2A). From Figure 3.3.2B, C and Table 3.3.1 of ITC 
experiments, the Kd value for the binding of EphA5 with Doxazosin Mesylate was 
6.64 μM, which was quite similar to the binding affinity between EphA5 and 
WDC/WTF peptides.  
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Figure 3.3.2: NMR and ITC characterization of the binding between EphA5 
and Doxazosin Mesylate. (A) Superimposition of the HSQC spectra of the 
15
N-labeled EphA5 in the absence (blue) and presence (red) of Doxazosin 
Mesylate at a molar ratio of 1:14. (B) ITC titration profiles of the binding reaction 
between EphA5 LBD and Doxazosin Mesylate. (C) Integrated values for reaction 
heat with subtraction of the corresponding blank results normalized by the amount 
of ligand injected versus Doxazosin Mesylate/EphA5 molar ratio. The detailed 
conditions and setting of the ITC experiments are presented in Materials and 
Methods as well as Table 3.3.1. 
 
 
Table 3.3.1: Thermodynamic parameters of the binding interactions between 
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3.3.2 Mapping of Binding Interface between EphA5 LBD and Doxazosin Mesylate 
by Chemical Shift Perturbation Analysis 
 From the NMR titration experiments, a gradual shift of the EphA5 HSQC 
peaks were observed, correlating with the increase concentration of Doxazosin 
Mesylate molecules, which suggested that the free and bond EphA5 molecules 
undergo a fast exchange on the chemical shift timescale. To further identify the 
exact binding interface of EphA5 ligand binding domain and Doxazosin Mesylate 
complex, chemical shift perturbation analysis was done upon titration of the small 
compounds.  
 As shown in Figure 3.3.2A, some of the HSQC peaks of the complex of 
EphA5 ligand binding domain and Doxazosin Mesylate shifted obviously 
compared to the free 
15
N-labeled EphA5 when the molar ratio of EphA5 to 
Doxazosin Mesylate reached 1:14. While when the molar ratio of EphA5 to 
Doxazosin Mesylate was higher than 1:5, the shift of many HSQC peaks was 
largely saturated and visible precipitation could be found inside the complex 
solution. Therefore, the chemical shift differences (CSD) between the free EphA5 
state and the complex state (the molar ratio of EphA5 to Doxazosin Mesylate was 
1:5) was calculated according to the formula ((Δ1H)2 + (Δ15N)2/5)1/2, and the results 
were plotted against EphA5 sequence as shown in Figure 3.3.3.  
 From the results, fifteen residues of EphA5 that gave shifted resonance peaks 
with significant CSD (peaks of EphA5 with CSD value larger than 0.1 ppm, more 
than 3.0 standard deviations from the mean CSD) and two residues of EphA5 that 
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with peaks disappeared were identified according to the sequence. Residues of 
M12 was located on the A-C loop, I28, G29 and E30 were located on the D 
β-strand, D32, E33 and Y35 were located on the D-E loop, H39 and T40 were 
located on the E β-strand, T75 on the G β-strand, E127 was on the J-K loop, N138 
on the K β-strand and I163, A164, V166, S167 and V168 were located on the M 
β-strand. All the identified residues of EphA5 ligand binding domain were labeled 
on the crystal structure of EphA5 as shown in Figure 3.3.4.  
 Previous research showed that D-E and J-K loops are the key component of 
the high affinity ephrin binding pocket of the Eph receptors (Himanen et al., 2009; 
Qin et al., 2008).  Very similar to the interaction between EphA5 and WDC 
peptides, in this chemical shift perturbation analysis, most of the residues with 
significant chemical shift differences (CSD) values were located inside the 
traditional binding pocket surrounded by D-E and J-K loops or on the D-E and 
J-K loops at the presence of 5-fold Doxazosin Mesylate. Therefore, the NMR 
titration results suggested that Doxazosin Mesylate probably also bind to the 
highly conserved high affinity ephrin-binding pocket of EphA5 ligand binding 
domain.  
  




Figure 3.3.3: Residue-specific chemical shift differences (CSD) of the EphA5 
ligand-binding domain in the presence of 5-fold Doxazosin Mesylate. Red bars 
indicate residues of EphA5 ligand-binding domain with CSD larger than 0.1 ppm 
(more than 3.0 standard deviations from the mean CSD). 
 
 
          
 
Figure 3.3.4: EphA5 ligand binding domain crystal structure with red color 
indicating residues of EphA5 with CSD larger than 0.1 ppm after binding 
with Doxazosin Mesylate. 
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3.3.3 Molecular Docking for EphA5 LBD and Doxazosin Mesylate 
 The structure of EphA5 ligand binding domain and Doxazosin Mesylate could 
not be calculated with NMR distance constraints due to the absence of 
intermolecular NOEs between them. The crystal structure of EphA5 and 
Doxazosin Mesylate was also difficult to get due to the gradually precipitation 
correlating to Doxazosin Mesylate addition. As a result, the modules of the EphA 
receptor ligand-binding domain in complex with the small molecules were 
constructed by use of the HADDOCK software (de Vries et al., 2007; Dominguez 
et al., 2003) in combination with CNS (Brunger et al., 1998). The x-ray structure 
of EphA5 ligand binding domain was used to build up the docking model. From 
the structures obtained from the computational docking, three complex structures 
with the lowest energies were selected for further display and analysis. 
As shown in Figure 3.3.5, docking models EphA5 LBD with Doxazosin 
Mesylate showed that Doxazosin Mesylate could bind to EphA5 in its conserved 
ephrin-binding pocket. Consistent to the large chemical shift perturbations of 
residues I28, G29, E30 and D32 of EphA5 showed as Figure 3.3.3, Doxazosin 
Mesylate mainly bind to the D-E loop and D, E beta-strand of EphA5 ligand 
binding domain.  
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Figure 3.3.5: Docking models of EphA5 ligand binding domain in complex 
with Doxazosin Mesylate. Stereo view of the superimposition of the unbound 
EphA5 structure (red) with the selected docking model in complex with 
Doxazosin Mesylate (blue). 
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3.4 NMR Dynamics Study of EphA5 LBD 
Nowadays, for determining the three dimensional structures of biological 
macromolecules, NMR has become a powerful technique the same as X-ray 
crystallography. Compared with X-ray crystallography, NMR is able to solve 
protein structures in solution. Based on different aims, the condition of protein 
solution such as salt concentration and pH can be adjusted and protein 
conformational changes can be traced. Furthermore, NMR is also used to study 
protein dynamics, protein folding and intermolecular protein interactions. In the 
previous sections, the crystal structure of EphA5 ligand binding domain was 
reported, and interactions between EphA5 ligand binding domain with different 
binding partner were discussed. As a complementary aspect for understanding the 
EphA5 ligand-binding domain, the dynamics of EphA5 in free state and in 
complex with other binding partners were also studied. 
 
3.4.1 Structure Properties of EphA5 LBD Studied by NMR 




N NMR HSQC spectra of EphA5 ligand 
binding domain showed a well-dispersed HSQC spectrum in both dimensions (~4 
ppm over 
1
H and ~26 ppm over 
15
N dimensions), indicating that NMR 
experiments would be suitable for further study of EphA5. However, the peak 
intensities of HSQC spectrum are not uniform, suggesting that some regions might 
undergo conformational exchanges on μs-ms time scale.  
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 A pair of triple-resonance NMR spectra, HNCACB and CBCA(CO)NH were 




C double-labeled EphA5 protein sample to obtain the 
preliminary backbone sequential assignment for EphA5. As a result, almost all 
177 residues were assigned except Leu6, Pro21, Pro37, Ile38, Tyr41, Val46, Ser58, 
Glu71, Pro83, Tyr113, Leu128, Asp129, Leu130, Val134, Pro146, Ser148, Ala161 
and Pro176, whose HSQC peaks could not be observed under the experimental 
conditions (Figure 3.2.3).  
 Previous study of NMR show that the chemical shift deviation of Cα, Cβ, Hα, 
and C=O from random coil value reflects the secondary structure of protein 
(Wishart and Sykes, 1994). After finishing all the chemical shift assignment, 
secondary structure of free EphA5 ligand-binding domain was calculated by both 
Cα and Cβ chemical shifts. Figure 3.2.5 and Figure 3.2.6 show that the secondary 
structures calculated by Cα and Cβ were consistent with the EphA5 crystal 
structure obtained by X-ray crystallography. The deviation of Cα is negative in 
most regions and the deviation of Cβ is positive in most regions, indicating that 
these regions are β-strands. To enhance the chemical shift differences, ΔCα-ΔCβ 
(differences of Cα-Cα0 and Cβ-Cβ0) was plotted to show the secondary structure 
characterization of EphA5 ligand binding domain. As shown in Figure 3.4.1, the 
positive Cα conformational shifts for the J-K loop residues Asp180-Glu181 and 
Gly189-Asp190 indicate that these two regions adopt a helical/loop-like 
conformation in solution, rather than an extended β-stranded conformation. This is 
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consistent with the information obtained from the crystal structure of the EphA5 
LBD.  
 
Figure 3.4.1: EphA5 LBD chemical shift deviation of ΔCα-ΔCβ.  
 
3.4.2 NMR Dynamics Study of Free EphA5 LBD 
3.4.2.1 Dynamics Study of Free EphA5 and Analysis of Relaxation Data 
 
15
N NMR relaxation data, including longitudinal relaxation time T1, 




N steady-state NOE (hNOE) could 
sensitively indicate the dynamics of protein local environment on the pico- to 
nano-second timescale as well as dynamic aggregation. The relaxation data of free 





NOE (hNOE) offers a reliable measure of the backbone flexibility (Clore et al., 
1990; Farrow et al., 1994; Palmer et al., 1991; Ran et al., 2008). Due to the 
overlap and /or weak intensity of many resonance peaks resulting from the relative 
large size and presence of many exposed loop residues, only 128 out of 172 
non-proline peaks are suitable for quantitative analysis. As shown in Figure 3.4.2C, 






N59 P79 Y99 S119 S139 D159 A179 V199 A219
Chemical shift deviation of ΔCα-ΔCβ 
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indicating these residues have significantly limited backbone conformational 
movement. Besides the N- and C-terminal residues, six additional regions also 
have low hNOE values. These include the A-C (Met70-Asp72), D-E 
(Glu88-Asn92), E-F (Met105-Asn108), G-H (Ser139-Cys147), I-J (Gly163-I166) 
and J-K (Asp180-Lys194) loops (Figures 5c,d). These results indicate that the loop 
regions are also intrinsically dynamic on the ps-ns time scale. In other words, 
many conformations co-exist over these loops, which are exchangeable on the 
ps-ns time scale. 
   
Figure 3.4.2: the 
15
N NMR backbone relaxation data of the EphA5 
ligand-binding domain in the 10 mM phosphate buffer (pH 6.3). (A) R1, 
inverse of 
15
N T1 (longitudinal) relaxation times. (B) R2, inverse of 
15
N T2 




N steady-state NOE intensities (hNOE). 
(D) EphA5 LBD structure with the residues having hNOE values < the average 
(0.65) colored in red.  
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3.4.2.2 Model-free Analysis of Free EphA5 Relaxation Data 
 In order to obtain a general description of diverse internal dynamics in the 
protein, an approach based on the “Model-free” formalism was used to analyze the 
NMR relaxation data of free EphA5 ligand binding domain (Fairbrother et al., 
1998; Fushman et al., 1997; Hall and Fushman, 2003; Lipari and Szabo, 1982). 
Isotropic, axially-symmetric and fully anisotropic models for the overall motions 
were examined and compared. Finally, a fully anisotropic model was selected and 
the parameters for the overall rotational diffusion of the free EphA5 LBD are 
shown in Supplementary Table S1. The analysis generated squared generalized 
order parameters, S
2
, which reflect the conformational rigidity on a ps-ns time 
scale. The regions with secondary structure have higher S
2
, indicating their 
rigidity at ps-ns time scale; the loop regions have lower S
2
, indicating their 
flexibility at ps-ns time scale, ranging from 0 for high internal motion to 1 for 
completely restricted motion in a molecular reference frame. As shown in Figure 
3.4.3A, the regions with secondary structure have higher S
2
 values, consistent with 
the high backbone rigidity, while the loop regions have smaller S
2
 values, 
consistent with high flexibility. In particular, the residues in the D-E, G-H and J-K 
loops have very low S
2
 values, in agreement with the conclusions from hNOE 
analysis (Figure 3.4.3A and C).  
Model-free analysis also yields the conformational exchange contribution 
values, Rex, which reflects conformational exchanges on µs-ms time scale. Only 
10 residues in the EphA5 LBD have Rex values >2 Hz, including residues 
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Gly87-Val89 in the D strand, Lys103 in the E-F loop, Leu134 in the G-H loop, 
Asn169-Gln170 in the I-J loop, Glu181 and Met193 in the J-K loop, Lys207 in the 
K-L loop (Figure 3.4.3B and D). 
      
Figure 3.4.3: Model-free analysis of the EphA5 LBD. (A) Generalized squared 
order parameter (S
2
) derived from the Model-free analysis of the relaxation data. 
(B) Residue-specific Rex values derived from the Model-free analysis of the 
relaxation data. (C) EphA5 LBD structure with the residues having S
2
 < the 
average (0.7) colored in green and those with S
2
 < the average – STD (0.5) in red. 
(D) EphA5 LBD structure with the residues having Rex > 2 Hz colored in cyan 
and those > 5 Hz colored in red.  
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3.4.2.3 Carr-Purcell Meiboom-Gill Relaxation Dispersion (CPMG RD) of Free 
EphA5 LBD 
 Carr-Purcell Meiboom-Gill Relaxation Dispersion (CPMG RD) is a powerful 
approach to obtaining kinetic, thermodynamic and structural information for 
exchange process of protein including side-chain reorientation, loop motion, 
secondary structure changes and hinged domain movement (Kleckner and Foster, 
2011). Here we used CPMG experiments that are sensitive to μs-ms timescale 
exchange dynamics between states, to probe motion in the free EphA5 system.  




N NMR spectra were recorded containing a fixed 
relaxation time, during which a variable number of spin-echos with different 
values of τ are applied sequentially. Each value of τ can alternatively be expressed 
as a CPMG frequency, νCPMG = 1/(4τ) that quantifies the rate of precession of 
magnetization about the axis of the applied RF pulse (Kleckner and Foster, 2011). 
A series of fourteen ‘spin-echo’ pulses with correlated CPMG frequency was 
applied to transverse magnetization during the relaxation delay (CPMG 
frequencies are 40, 80, 120, 160, 200, 240, 320, 400, 480, 560, 640, 720, 800, 960 
Hz) for EphA5 sample.  
In general, the magnetization vectors could be refocused by the spin-echo if 
each individual vector exhibits the same average chemical shift. While if exchange 
causes a spin to experience a different chemical shift, then the incomplete 
refocusing among the ensemble of molecules and would lead to signal broadening 
which will lead to peak intensity differences of the NMR spectra (Kleckner and 
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Foster, 2011). The intensity differences between the NMR spectra of CPMG 
frequency 40 Hz and 960 Hz were plotted against EphA5 ligand binding domain 
protein sequence. As shown in Figure 3.4.4, only three residues were detected 
with R2 (cp) > 1.5 Hz. Together with the Rex results from the Model-free 
analysis, this indicates that there is no significant conformational exchange over 
the EphA5 LBD on µs-ms time scale (Baldwin and Kay, 2009; Boehr et al., 2010; 
Kleckner and Foster, 2011; Loria et al., 2008; Palmer, 2009). Thus, in the unbound 
state the EphA5 LBD does not appear to have global conformational exchanges on 
the µs-ms time scale.  
           
Figure 3.4.4: Dynamics of the free EphA5 LBD in the μs-ms time scale as 
revealed by CPMG-dispersion measurements. (A) Difference of effective 
transverse relaxation rate R2(cp) at 80 and 960 Hz. Only three residues have 
R2(cp) >1.5 Hz. (B) Crystal structure of the EphA5 LBD with residues having 
R2(cp) > 1.5 Hz displayed as spheres. 
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3.4.2.4 H/D Exchange Experiment for Free EphA5 Ligand Binding Domain 
 The NMR hydrogen/deuterium (H/D) exchange experiment was conducted to 
assess the backbone dynamics of the EphA5 ligand-binding domain on min-hr 
timescale. As well established, in solution labile hydrogen such as amide protons 
on proteins are continually exchanging with the solvent at different rates, 
depending on a variety of factors associated with their environment including their 
exposure to the solvent or their involvement in H-bonds. Consequently, amide 
H/D exchange experiments offer a sensitive reflection of the exposure degree of 
amide protons to the solvent (Krishna et al., 2004; Qin et al., 2012). As shown in 
Figure 3.4.5A and C, upon subjecting to H/D exchange, around 58% of the 172 
non-proline residues in the EphA5 LBD have completely exchanged with 
deuterium with the experimental dead time (15 min). These fast-exchange rate 
residues located not only on the loop and helical regions, but also on the 
beta-strands, particularly in the D and E strands (Figure 3.4.5C). After 2 hours, 
amide protons of additional residues undergo exchanges and only around 27% of 
the total residues have the HSQC peaks, which mostly located on the beta-stands 
(Figure 3.4.5C) and defined as slow-exchange-rate residues. After 24 hours, only 
around 19% of the total residues have persisted HSQC peaks (Figure 3.4.5B and 
D). These results suggest that the loop region of EphA5 ligand-binding domain is 
highly dynamic on the min-hr timescale. 
 
  




Figure 3.4.5: NMR hydrogen-deuterium (H/D) exchange for free EphA5 




N NMR HSQC spectra 
of the 
15
N-labeled EphA5 LBD (blue) and 15 min after the lyophilized EphA5 





NMR HSQC spectra of the 
15
N-labeled EphA5 LBD, 15 min (blue) and 24 hr (red) 
after the lyophilized EphA5 LBD powder was re-dissolved in D2O. (C) The 
structure of the EphA5 LBD with residues whose HSQC peaks were not detected 
even in buffer colored in green, residues whose backbone amide protons 
completely exchanged within 15 min in blue, residues whose backbone amide 
protons persisted after 15 min but completely exchanged in 2 hours in yellow and 
residues whose backbone amide protons persisted even after 2 hours in red. 
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3.4.3 NMR Dynamics Study of EphA5 LBD with WDC Peptide 
3.4.3.1 Dynamics Study of EphA5 LBD with WDC Peptide and Analysis of 
Relaxation Data 
As shown in Figure 3.2.5 and Figure 3.2.6, compare the secondary structures 
calculated for free EphA5 and EphA5 binding with WDC peptide, the binding of 
WDC to EphA5 did not induce significant conformational changes to the 
secondary structure of EphA5 ligand binding domain. The relaxation data of 





N steady-state NOE (hNOE) offers a reliable measure to the backbone 
flexibility. Similar to the free EphA5 ligand binding domain, as shown in Figure 
3.4.6A and B, most residues forming secondary structures have hNOE values 
higher than 0.75, indicating these residues have significantly limited backbone 
conformational movement. As shown in the figure, loop regions of EphA5 ligand 
binding domain have lower hNOE values. Residue G142 to C147 on the G-H loop 
has an average hNOE value of around 0.54, and residue D180 to L195 on the J-K 
loop has an average hNOE value of 0.54, compared to the values of free EphA5 
ligand binding domain, indicating that these loop regions are more rigid with 
certain flexibility.  
 
  96 
      
 
Figure 3.4.6: the 
15
N NMR backbone relaxation data of the EphA5 
ligand-binding domain with 3-fold WDC peptide in the 10 mM phosphate 





N steady-state NOE intensity bars. (C) R1, inverse of 
15
N T1 
(longitudinal) relaxation times. (D) R2, inverse of 
15
N T2 (transverse) relaxation 
times. 
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3.4.3.2 Carr-Purcell Meiboom-Gill Relaxation Dispersion (CPMG RD) of EphA5 
LBD with WDC Peptide 
 Carr-Purcell Meiboom-Gill Relaxation Dispersion (CPMG RD) was also used 
to probe motion in the EphA5 ligand-binding domain with 3-fold WDC peptide 
complex system, for its sensitivity to analysis μs-ms timescale exchange dynamics. 
A series of fourteen ‘spin-echo’ pulses with correlated CPMG frequency was 
applied to transverse magnetization during the relaxation delay (CPMG 
frequencies are 40, 80, 120, 160, 200, 240, 320, 400, 480, 560, 640, 720, 800, 960 
Hz) for EphA5 LBD with WDC peptide sample.  
As shown in Figure 3.4.7, compared to the CPMG data of free EphA5 ligand 
binding domain, there are 27 residues with R2 (cp) > 1.5 Hz, indicating the 
complex of EphA5 ligand binding domain with WDC peptide exhibits some 
exchanges in solution within μs-ms timescale.  
 
 
Figure 3.4.7: CPMG data analysis for EphA5 ligand binding domain with 
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3.4.3.3 H/D Exchange Experiment for EphA5 LBD with 3-fold WDC Peptide 
 The NMR hydrogen/deuterium (H/D) exchange experiment was conducted to 
assess the backbone dynamics of the EphA5 ligand-binding domain in present of 
3-fold WDC peptide on min-hr timescale. As shown in Figure 3.4.8A, upon 
subjecting to H/D exchange, around 53% of the total residues have completely 
exchanged with deuterium with the experimental dead time (15 min) compared to 
58% for the free EphA5 ligand binding domain. These fast-exchange rate residues 
located not only on the loop and helical regions, but also on the beta-strands 
(Figure 3.4.8C). After 2 hours, around 37% of the total residues have the HSQC 
peaks (Figure 3.4.8B) compared to 27% for the free EphA5 ligand binding domain, 
which located on the beta-stands and the loop regions (Figure 3.4.8C) and defined 
as slow-exchange-rate residues. After 24 hours, around 33% of the total residues 
have persisted HSQC peaks (data now shown), compared to 19% for the free 
EphA5 ligand binding domain. In solution labile hydrogen such as amide protons 
on proteins are continually exchanging with the solvent at different rates, 
depending on a variety of factors associated with their environment including their 
exposure to the solvent or their involvement in H-bonds. As shown in Figure 
3.4.5C and Figure 3.4.8C, most differences located in or around the ephrin ligand 
binding channel, especially the D-E and J-K loop regions. For this case, these 
different results indicate that the interaction between WDC peptide and the EphA5 
LBD inside the ligand-binding channel affected the dynamics of EphA5 ligand 
binding domain on the min-hr timescale, in agreement with the previous analysis. 
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By adding the WDC peptide, the H/D exchange rate of some residues might be 
decreased or stopped by involving in H-bonds formation between WDC and 
EphA5 ligand binding domain, some fast-exchange rate residues became 
slow-exchange rate residues due to the interaction of WDC and EphA5 LBD. 
    
 
Figure 3.4.8: NMR hydrogen-deuterium (H/D) exchange for EphA5 ligand 





NMR HSQC spectra of the 
15
N-labeled EphA5 LBD with WDC (blue) and 15 min 
(red) after the lyophilized EphA5 LBD with WDC sample powder was 




N NMR HSQC spectra of 
the 
15
N-labeled EphA5 LBD with WDC, 15 min (blue) and 2 hr (red) after the 
lyophilized EphA5 LBD with WDC sample powder was re-dissolved in D2O. (C) 
The structure of the EphA5 LBD with the H/D exchange results mapped onto. 
Blue: the residues completely exchanged with 15 min; green: residues completely 
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3.4.4 H/D Exchange Experiment for EphA5 LBD with 5-fold Doxazosin Mesylate 
 The NMR hydrogen/deuterium (H/D) exchange experiment was also 
conducted to assess the backbone dynamics of the EphA5 ligand-binding domain 
in present of 5-fold Doxazosin Mesylate compound on min-hr timescale. As 
shown in Figure 3.4.9A, upon subjecting to H/D exchange, around 68% of the 
total residues have completely exchanged with deuterium with the experimental 
dead time (15 min) compared to 58% for the free EphA5 ligand binding domain 
(Figure 3.4.9C). After 2 hours, around 24% of the total residues have the HSQC 
peaks which located on the beta-stands and the loop regions (Figure 3.4.9B and C) 
and defined as slow-exchange-rate residues. After 24 hours, around 18.6% of the 
total residues have persisted HSQC peaks (data now shown). As shown in Figure 
3.4.5C, Figure 3.4.8C and Figure 3.4.9C, most of the residues showing differences 
located in or around the ephrin ligand binding channel, including J and K 
beta-strands, especially the D-E and J-K loop regions. These different results 
indicate that dislike the interaction between WDC peptide and the EphA5 LBD, 
the interaction of EphA5 LBD and Doxazosin Mesylate compound did not affect 
the dynamics of EphA5 ligand binding domain dramatically on the min-hr 
timescale. Although some of the residues showing increasing the H/D exchange 
rate rather than decreasing the H/D exchange rate after adding Doxazosin 
Mesylate, no conclusion could be got until more quantificational experiments 
could be done.  
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Figure 3.4.9: NMR hydrogen-deuterium (H/D) exchange for EphA5 ligand 




N NMR HSQC spectra of the 
15
N-labeled EphA5 LBD with Doxazosin 
Mesylate (blue) and 15 min (red) after the lyophilized EphA5 LBD with 
Doxazosin Mesylate complex sample powder was re-dissolved in D2O. (B) 




N NMR HSQC spectra of the 
15
N-labeled EphA5 
LBD with Doxazosin Mesylate, 15 min (blue) and 2 hr (red) after the lyophilized 
the sample powder was re-dissolved in D2O. (C) The structure of the EphA5 LBD 
with the H/D exchange results mapped onto. Blue: the residues completely 
exchanged with 15 min; green: residues completely exchanged from 15 min to 2 
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3.4.5 PFG Diffusion Measurements for EphA5 LBD in Free State or with 
Peptides/compound 
 Numerous proteins are now recognized to depend on oligomerization for 
biological activity or receptor binding, so it’s important to know the oligomeric 
state of protein sample before further structural and functional analysis. 
Self-diffusion is defied as translational motion reflecting the random motions of a 
molecule in the absence of a concentration gradient. The coefficient of this motion, 
Ds, is related to the average molecular size. The pulsed field gradient (PFG) NMR 
self-diffusion measurements can be used to measure the coefficient Ds and 
demonstrate the aggregation state of protein systems under conditions identical to 
those used in structure determination and relaxation data analysis (Altieri et al., 
1995; Jansma et al., 2010).   
 As shown in Figure 3.4.10, the free EphA5 ligand binding domain has a Ds 




/s. These values are very similar to that of the EphA4 LBD 




/s). This supports the 
notion that the EphA5 LBD is a monomer in solution, as previously demonstrated 
for the EphA4 LBD using a variety of techniques (Bowden et al., 2009; Qin et al., 
2008; Singla et al., 2010). 
Assuming the interaction as hard-sphere molecular contacts, the dimer to 
monomer ratio of the diffusion coefficients was estimated to be 0.75 calculated 
from the Strokes-Einstein equations (Altieri et al., 1995). The Ds value of EphA5 




/s, the Ds value of EphA5 LBD with 
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/s, and the Ds value of EphA5 LBD with 




/s. The Ds values measured for the 
complexes and free EphA5 LBD are quite similar, and the ratio of Ds, complex to Ds, 
free EphA5 is 95% to 96%. These results of PFG diffusion measurements for EphA5 
LBD in free state or complex indicate that adding antagonistic peptides or small 
compounds would not induce oligomerization or aggregation of EphA5 ligand 
binding domain. EphA5 ligand binding domain is a monomer in NMR 
experiments studies.  
 
 
Figure 3.4.10: PFG diffusion analysis of EphA5 ligand binding domain in free 
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3.5 Discussion for EphA5 Ligand-Binding Domain 
To understand the structural and dynamic mechanisms controlling the ligand 
binding specificity of Eph receptors, in the present study we determined the 
crystal structure of the EphA5 LBD without any bound ligand at a resolution of 
2.9 Å. Remarkably, except for the C-terminal three residues, all residues of the 
EphA5 LBD including those in D-E and J-K loops are visible. Overall, the EphA5 
LBD has the same jellyroll β-sandwich architecture shared by all Eph LBDs with 
structures previously determined. Nevertheless, EphA5 residues Ala179-Ser182 
and Gly189-Met193 in the J-K loop assume helical-like conformations in the 
crystal structure, unlike the unbound EphA2, EphA4 and EphB2 LBDs, in which 
the corresponding residues form a short β-sheet. Further analysis of NMR Cα 
chemical shifts indicates that these residues also adopt a helical-like conformation 
in solution. Furthermore, comparison with the other available Eph receptor LBD 
structures surprisingly reveals that the J-K loop conformation of EphA5 in the 
unbound state resembles those of other Eph receptor LBDs in complex with 
ephrins.  
This structural feature likely enables the unique binding selectivity of the 
EphA5 LBD towards different ligands. To test the activity of the EphA5 LBD 
structure, two antagonistic peptides, WDC and WTF and one agonistic small 
compound, Doxazosin Mesylate was used. All the three components could bind to 
EphA5 LBD in the conserved ephrin-binding channels with different binding 
affinities. For example, the EphA5 LBD is able to bind WDC, a peptide that is 
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highly selective for EphA5, with a Kd of 6.22 µM. However, it shows no 
detectable ability to interact with C1, an antagonistic small molecule that 
preferentially targets the EphA2 and EphA4 LBDs, which have a short β-sheet 
within their J-K loop.  
 The role of protein dynamics in modulating protein-ligand interactions is only 
beginning to be delineated. The differential dynamics on different time scales may 
explain the variable binding affinities and specificities observed for different Eph 
receptor LBDs, even though they have the same overall fold. Indeed, we have 
recently demonstrated that the widely variable loop conformations observed in 
different EphA4 LBD crystal structures are correlated with the co-existence of 
multiple conformations in solution, which are interconvertible on the ps-ns time 
scale. On the other hand, it appears that the binding to ephrins shifts the 
equilibrium of the conformation assembly of the EphA4 LBD from the closed 
form characterized by the presence of a short β-sheet in the J-K loop, which is 
populated in the free state, to an open form where the short β-sheet is transformed 
into a helical-like conformation. Because of a relatively large energy barrier, the 
exchange between the closed and open conformations likely occurs on a slower 
(µs-ms) time scale.  
In this study, we have further utilized NMR spectroscopy to assess the 
dynamic features of the EphA5 LBD on three time scales: ps-ns, µs-ms and min-hr. 
Analysis of NMR backbone relaxation data show that, similar to what was 
observed for EphA4, the EphA5 loop regions also have high backbone dynamics 
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on the ps-ns time scale. This implies that the loops can have multiple 
conformations that co-exist in solution and that are exchangeable on the ps-ns 
time scale. Interestingly, these unusually high dynamics of the D-E strands and 
loop appear to lead to high solvent exposure of the high affinity ephrin-binding 
pocket of EphA5. This notion is experimentally supported by the H-D exchange 
experiments, which show that many residues in the EphA5 D-E strands and loop 
have their backbone amide protons completely exchanged with deuterium within 
the 15 min dead time of the experiment, while the corresponding residues in the 
EphA4 LBD remain unexchanged even after 24 hours. 
 Model-free analysis indicates that very limited conformational exchanges 
exist in the EphA5 LBD on the µs-ms time scale, which is further confirmed by 
the CPMG-based relaxation dispersion measurements. These results do not 
support the existence of multiple conformations of the EphA5 LBD with large 
structural differences that would require microseconds to milliseconds to 
interconvert. We therefore propose that unlike the EphA4 LBD, which has very 
different J-K loop conformations in the free and ephrin-bound states, the EphA5 
LBD has very similar conformations in both the free and ephrin-bound states. 
Supporting this notion, in the free state the populated conformations of the EphA5 
LBD are already highly similar to the open form for the EphA2, EphA4 and 
EphB2 LBDs in complex with ephrins. Therefore, the EphA5 LBD conformations 
populated in the free state, which are characterized by multiple loop 
conformations exchangeable on the ps-ns time scale, are likely ready to bind 
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ephrin-A ligands. On the other hand, the unusual dynamics of the EphA5 D-E loop 
may depend on the unique conformation of the J-K loop. Because the J-K loop has 
no large conformational exchanges on the µs-ms time scale, the D-E loop has to 
be more dynamic on the ps-ns time scale to facilitate the insertion of the ephrin 
G-H loop. Taken together, our results suggest that the EphA5 receptor may be 
capable of binding ephrin-A ligands by undergoing only minor rearrangements of 
the D-E, G-H and J-K loops, which are facilitated by their high intrinsic dynamics 
on the ps-ns time scale.  
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3.6 EphA7 Ligand-Binding Domain 
3.6.1 Expression and Purification of EphA7 LBD 
The recombinant his-tag protein of EphA7 ligand-binding domain was over 
expressed in E. coli Rosetta-gami (DE3) cells (Novagen) to get the correct 
formation of disulfide bonds. The harvested cells were sonicated in the PBS lysis 
buffer to release soluble His-tag EphA7 proteins. Then the recombinant proteins 
were subsequently purified under native condition and cleaved by in-gel cleavage 
at room temperature with thrombin overnight. The released EphA7 protein was 
purified on an AKTA FPLC machine using a gel filtration column. The whole 
expression and purification process and the purity of the purified protein were 
assessed by SDS-PAGE using 15% gel.  
For the crystallization of EphA7 LBD, the harvested cells were sonicated in 
Tris buffer. To increase the purity of the protein, the eluted fractions from gel 
filtration step were then purified by ion-exchange chromatography using 
anion-exchange column (Mono Q 10/100) after purified by gel filtration column. 
The purity of the protein was verified by the SDS-PAGE, and the identity of 
EphA7 was verified by MALDI-TOF mass spectrometry (data not shown). 
 
3.6.2 Structural Characterization of EphA7 LBD by CD 
 The structural properties of EphA7 ligand-binding domain were fist 
investigated by far-UV CD spectroscopy. As shown in Figure 3.6.1A, the spectrum 
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of EphA7 protein in 10mM phosphate buffer (pH 6.3) had a maximal negative 
peak at around 212 nm, which implied that EphA7 ligand-binding domain has a 
typical β-conformation. The near-UV CD spectra of EphA7 in the absence and 
presence of 8 M urea were also done to see the overall tertiary packing (Figure 
3.6.1B). The near-UV spectra showed that without the 8 M urea, EphA7 adopted 
tight tertiary packing, while the property was lost under denatured condition with 
8 M urea. All the data were from three independent scans and were added and 
averaged. 
 
Figure 3.6.1: Preliminary structural characterization of EphA7 ligand 
binding domain by CD. (A) Far-UV CD spectrum of 20 µM EphA7 in the 10 
mM phosphate buffer (pH 6.3). (B) Near-UV CD spectra of EphA7 in 10 mM 
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3.6.3 NMR Structural Characterization of EphA7 LBD 
 NMR HSQC experiment was used to further assess the structural properties of 
the EphA7 ligand-binding domain, which is a sensitive probe to both secondary 




N NMR HSQC 
spectra of EphA7 ligand binding domain showed a well-dispersed HSQC 
spectrum in both dimensions (~4 ppm over 
1
H and ~25 ppm over 
15
N dimensions), 
indicating that this protein had a well-packed tertiary structure as confirm by the 
CD spectra. Therefore, NMR experiments would be suitable for studying the 
structure of EphA7, binding affinity of EphA7 interacting with its ligands.  
 





N HSQC spectrum of the EphA7 ligand-binding domain 
collected in a phosphate buffer at pH 6.3. 
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3.6.4 Crystal Structure of EphA7 LBD  
The EphA7 ligand binding domain was prepared in a buffer containing 25 
mM Tris-HCl (pH 7.8), 150 mM NaCl and 5 mM CaCl2 at a concentration of 10 
mg/ml. Crystal screen was set up by preparing 1 μl of the protein solution mixed 
with 1μl of the reservoir solution as hanging drops at room temperature in a well 
containing the reservoir solution. Rock-like crystals formed in the well containing 
1.4 M sodium chloride, 0.1 M sodium acetate trihydrate, and pH 4.6 after 3 days. 
 
3.6.4.1 Structure of EphA7 LBD Determined from Crystal 
X-ray diffraction images for a single crystal were collected using an in-house 
Bruker X8 PROTEUM x-ray generator with a CCD detector. The crystal was 
protected by cryoprotectant (1.4 M sodium chloride, 0.1 M sodium acetate 
trihydrate, 25% glycol, pH 4.6). The data were indexed and scaled in the space 
group C2221 (a=128.89, b=138.32, c=143.31), with six molecules per asymmetric 
unit (AU), using the program HKL2000. The Matthews coefficient was 2.6 with 
52.75% solvent constant. 
The crystal structure of EphA7 ligand binding domain was determined by the 
Molecular Replacement method using EphA4 ligand binding domain (Protein 
Data Bank code 3CKH) as a search module using Phaser and MolRep in the Suite 
CCP4. The crystal structure was subsequently completed by manual fitting with 
the program COOT and further refined with program suite Crystallography & 
NMR System (CNS) (Brunger et al., 1998) at 3.0 Å resolution with a final 
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R-factor of 0.2468 (Rfree=0.3220). The final structure was analyzed by 
PROCHECK, and details of the data collection and refinement statistics are shown 
in Table 3.6.1.  
As shown in Figure 3.6.3, there are six molecules in one asymmetric unit 
(AU). The EphA7 ligand-binding domain adopts the jellyroll folding architecture, 
identical to other previous revealed Eph receptors (Figure 3.6.4). The jellyroll 
consists of 11 anti-parallel beta-sheets arranged as a compact beta-sandwich, 
which connected by loops of different length and two disulfide bonds. Most of the 
electron density map is complete for EphA7 LBD structure. While dislike the 
crystal structure of EphA5 LBD, the J-K loops are partially invisible, like some 
previous determined unbound Eph receptor LBD structures. This might due to the 
high intrinsic dynamics of the loop regions. 
      
Figure 3.6.3: Pattern of the EphA7 LBD clusters. 
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Table 3.6.1: Crystallographic data and refinement statistics for the EphA7 
ligand-binding domain structure. 
 
 Data collection  
 Wavelength (Å) 1.5418 
 Resolution range (Å) 50.0 to 3.0 
 Space group C222(1) 
 Cell parameters  
 a, b, c (Å) 128.89, 138.32, 143.31, 
 α, β, γ (°) 90, 90, 90 
 Observed Reflections 305369 
 Unique Reflections 26019 
 Redundancy 11.9 
 Completeness (%) 94.92 
 Overall (I/σI) 13.809 
 Rsym 0.133 
 Refinement  
 Resolution range (Å) 50.0 to 3.0 
 Rwork* 0.2468 
 No. of reflections 25996 
 Rfree** 0.3220 
 No. of reflections 1418 
 RMSD bond lengths (Å) 0.0104 
 RMSD bond angles (°) 1.655 
 Ramachandran Plot  
 Most favored region (%) 66.1 
 Additional allowed regions (%) 28.4 
 Generously allowed regions (%) 4.4 
 Disallowed regions (%) 1.1 
 B-factors  
 Protein 24.261 
 Water 23.907 
 
*Rwork= Σ |Fobs - Fcalc|/ ΣFobs where Fcalc and Fobs are the calculated and observed 
structure factor amplitudes, respectively. 
**Rfree=as for Rwork, but for 10.3% of the total reflections chosen at random and 
omitted from refinement. 
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Figure 3.6.4: Comparison between 6 EphA7 LBD structures.  
 
 
3.6.4.2 Comparison between 6 EphA7 LBD Structures and Previous EphA7 
Structures 
 Comparison of the six EphA7 LBD structures shows that except for the loop 
regions, the regions with secondary structure are highly superimposed (Figure 3.6.4). 
For the loop regions, especially A-C, D-E, G-H and J-K loop region, the adoption of 
various conformations shows their high flexibility.  
The previous released EphA7 LBD crystal structure (3NRU) was expressed in 
an insect system. Although our EphA7 LBD protein was expressed in E.coli, the 










(Figure 3.6.5). This pattern of disulfide bonds is identical to that observed 
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previously in other EphA and EphB receptor ligand binding domains. The 
previous released EphA7 LBD crystal structure (3NRU) adopts 12 molecules in 
one asymmetric unit (AU), and they are almost the same except for some small 
differences in the loop regions. As shown in Figure 3.6.5, compare our EphA7 
LBD structure with the previous one, only the loop regions show some 
differences.  
           
Figure 3.6.5: Comparison of our solved EphA7 LBD structure with the 
previous released EphA7 structure (3NRU). The disulfide bonds of our EphA7 
LBD structure are colored in red. Our solved EphA7 LBD structure is green and 
the previous released EphA7 structure (3NRU) is blue. 
 
 The structure of EphA7 ligand binding domain bears a highly similar jellyroll 
folding architecture composed of 11 antiparallel beta-stands to the previously 
determined ligand binding domains of the EphA2, EphA4, EphB2 and EphB4 
receptors (Figure 3.6.6). The backbone r.m.s.d. of the EphA7 ligand binding 
domain over 11 beta-strands are quite small compared with the previous solved 
Eph receptor structures. On the other hand, although failed to compare the J-K 
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loop region of the structures due to the invisibility of J-K loop of EphA7, very 
large variations could be observed for the D-E loop regions, which are critical for 
ligand binding, not only between EphA7 and the EphB receptors but also between 
Eph receptors from the same A- or B-subclasses.  
 
          
Figure 3.6.6: Structure comparison. Stereo view of the superimposition of 
EphA7 LBD structure (blue) with previously determined EphA2 (3C8X), EphA4 
(3CKH) and EphB2 (3ETP) structures.  
 
 
3.6.5 Structure Properties of EphA7 LBD Studied by NMR 




N NMR HSQC spectra of EphA7 ligand 
binding domain showed a well-dispersed HSQC spectrum in both dimensions (~4 
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ppm over 
1
H and ~25 ppm over 
15
N dimensions), indicating that NMR 
experiments would be suitable for further study of EphA7.  
 A pair of triple-resonance NMR spectra, HNCACB and (H)CC(CO)NH were 




C double-labeled EphA7 protein sample to obtain the 
preliminary backbone sequential assignment for EphA7. Almost all 177 residues 
were assigned except Lys1, Glu2, Val3, Lys9, Pro21, Pro22, Pro37, Pro49, Asn64, 
Pro83, Asp101, Arg106, Arg109, Pro146 and Ala161, whose HSQC peaks could 
not be observed under the experimental conditions (Figure 3.6.7).  
 After finishing all the chemical shift assignment, secondary structure of free 
EphA7 ligand-binding domain was also calculated by both Cα and Cβ chemical 
shifts. Figure 3.6.8 A and B showed that the secondary structures calculated by Cα 
and Cβ. The deviation of Cα is negative in most regions and the deviation of Cβ is 
positive in most regions, indicating that these regions are β-strands. To enhance 
the chemical shift differences, as shown in Figure 3.6.8C, ΔCα-ΔCβ (differences 
of Cα-Cα0 and Cβ-Cβ0) was plotted to show the secondary structure 
characterization of EphA7 ligand binding domain. Similar to other Eph receptors, 
EphA7 is also composed of β-strands together with some loops.  
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Figure 3.6.8: EphA7 LBD chemical shift deviations provide insights in its 
secondary structure. (A) Chemical shift deviation of Cα. (B) Chemical shift 
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3.6.6 Interactions of EphA7 LBD with small molecules 
  Binding Interactions between EphA7 Ligand-binding Domain and 
Doxazosin Mesylate was also investigated by NMR titration experiments. For 
visible precipitations would form with adding the Doxazosin Mesylate solutions 
into the EphA7 ligand binding domain samples, ITC experiment failed and need to 
be further optimized. While the NMR experiments clearly showed that Doxazosin 
Mesylate have interaction with the ligand-binding domain of EphA7.  
As shown in Figure 3.6.9, the NMR spectra showed that some of the HSQC 
peaks of the complex of EphA7 ligand binding domain and Doxazosin Mesylate 
shifted obviously compared to the free 
15
N-labeled EphA7 when the molar ratio of 
EphA7 to Doxazosin Mesylate reached 1:14. From the NMR titration experiments, 
several peaks of the EphA7 HSQC spectra shifted gradually, correlating with the 
increase concentration of Doxazosin Mesylate molecules, which suggested that 
the free and bond EphA7 molecules undergo a fast exchange on the chemical shift 
timescale. To further identify the exact binding interface of EphA7 LBD with 
Doxazosin Mesylate complex, chemical shift perturbation analysis was done upon 
titration of the small compounds. 
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Figure 3.6.9: Characterization of the binding between EphA7 and Doxazosin 
Mesylate studied by NMR. Superimposition of the HSQC spectra of the 
15
N-labeled EphA7 in the absence (blue) and presence (red) of Doxazosin 
Mesylate at a molar ratio of 1:14.  
 
 
 Compared to the binding between EphA5 and Doxazosin Mesylate which 
most of the EphA5 HSQC peaks shifted more or less after adding Doxazosin 
Mesylate, most of the EphA7 HSQC peaks remain the same after adding 
Doxazosin Mesylate and only several of them showed shifts (Figure 3.3.2 and 
Figure 3.6.9). The chemical shift differences (CSD) between the free EphA7 state 
and the complex state was calculated according to the formula ((Δ1H)2 + 
(Δ15N)2/5)1/2, and the results were plotted against EphA7 sequence as shown in 
Figure 3.6.10.  
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Figure 3.6.10: Residue-specific chemical shift differences (CSD) of the EphA7 
ligand-binding domain in the presence of Doxazosin Mesylate.  
 
 From the results, eleven residues of EphA7 that gave shifted resonance peaks 
with significant CSD (peaks of EphA7 with CSD value larger than 0.05 ppm, 
more than 3.0 standard deviations from the mean CSD). Residues S29 was located 
on the D β-strand, D32, Q42 and V43 were located on the E β-strand, T75 on the 
G β-strand and gave the largest CSD value, D78 and C79 were located on the G-H 
loop, D122, F125, T126 and L130 was on the J-K loop and V166 was located on 
the M β-strand. All the identified residues of EphA7 ligand binding domain were 
labeled on the crystal structure of EphA7 as shown in Figure 3.6.11. Similar to the 
binding between EphA5 and Doxazosin Mesylate, all these residues given high 
CSD values are located inside the traditional binding pocket of EphA7 ligand 
binding domain surrounded by D-E and J-K loops or on the D-E and J-K loops. 
While compared to EphA5, fewer residues are involved in the interaction and the 
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Figure 3.6.11: Crystal structure of EphA7 ligand binding domain with red 
color indicating residues of EphA7 with CSD larger than 0.05 ppm after 
binding with Doxazosin Mesylate. 
 
3.6.7 H/D Exchange Experiment for Free EphA7 LBD 
 The NMR hydrogen/deuterium (H/D) exchange experiment was conducted to 
assess the backbone dynamics of the EphA7 ligand-binding domain on min-hr 
timescale. As shown in Figure 3.6.12A and C, upon subjecting to H/D exchange, 
around 58% of the total residues have completely exchanged with deuterium with 
the experimental dead time (15 min). These fast-exchange rate residues located 
not only on the loop and helical regions, but also on the beta-strands (Figure 
3.6.12C). After 2 hr, only around 29% of the total residues have the HSQC peaks 
(Figure 3.6.12B) which mostly located on the beta-stands (Figure 3.6.12C) and 
defined as slow-exchange-rate residues. After 24 hr, around 26% of the total 
residues have persisted HSQC peaks. These results suggest that the EphA7 
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Figure 3.6.12: NMR hydrogen-deuterium (H/D) exchange for free EphA7 




N NMR HSQC spectra 
of the 
15
N-labeled EphA7 LBD (blue) and 15 min after the lyophilized EphA7 





NMR HSQC spectra of the 
15
N-labeled EphA7 LBD, 15 min (blue) and 24 hr (red) 
after the lyophilized EphA7 LBD powder was re-dissolved in D2O. (C) The 
structure of the EphA7 LBD with residues whose HSQC peaks were not detected 
even in buffer colored in green, residues whose backbone amide protons 
completely exchanged within 15 min in blue, residues whose backbone amide 
protons persisted after 15 min but completely exchanged in 2 hours in yellow and 
residues whose backbone amide protons persisted even after 2 hours in red. 
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3.6.8 Discussion 
The crystal structure of EphA7 ligand-binding domain was solved. Unlike 
EphA5, this crystal structure of EphA7 has six molecules in one asymmetric unit 
(AU). It bears a highly similar jellyroll folding architecture composed of 11 
antiparallel beta-stands to the previous determined ligand binding domains 
structures. While by conducting the H-D exchange experiments and mapping the 
binding site of Doxazosin Mesylate, we can tell that the protein dynamic property 
and binding affinity of EphA7 is different from EphA5. When binding to 
Doxazosin Mesylate, although Dox could bind to both ephrin-binding channel of 
EphA7 and EphA5, it clearly binds to EphA5 with a much higher affinity and with 
more residues involved. The results of H-D exchange experiments also showed 
that although EphA7 and EphA5 have the same jellyroll folding architecture, 
dynamic properties of their loop regions are quite different. After 24 hours, around 
26% of the total residues of EphA7 have persisted HSQC peaks, while for EphA5, 
it only have 19% left. This result suggests the ligand-binding domain of EphA7 is 
more rigid than EphA5 in a min-hr time scale, although its loop regions are also 
very flexible. Compared to the “open” form that EphA5 adopts most of the time, 
EphA7 may adopts a “close” form when it is in the unbound state.  
A previous study showed that co-expression of a truncated form of EphA7 
suppresses tyrosine phosphorylation of the full-length EphA7 receptor and shifts 
the cellular response from repulsion to adhesion in vitro (Holmberg et al., 2000). 
And a soluble splice variant of EphA7 (EphA7
TR
) can interfere with full-length 
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EphA2 and blocks oncogenic signals in lymphoma cells (Oricchio et al., 2011). 
This study proved that EphA7 receptor could act as a tumor suppressor in 
follicular lymphoma with immediate therapeutic potential. With the availability of 
EphA7 LBD crystal structure, the interaction characterizations of above studies 
could be invested deeper in a different aspect. Furthermore, the design of 
antagonistic/agonistic molecules with high affinity and specificity might be 
achieved by targeting a special dynamic state of the Eph LBDs, although they 
have the same jellyroll β-sandwich fold. 
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3.7 Nogo-54 in Medaka Fish 
3.7.1 Expression and Purification of Nogo-54 
 The recombinant his-tag Nogo-54 protein was expressed in the bacterial strain 
BL21. The harvested cells were sonicated in the PBS lysis buffer to release 
soluble His-tag Nogo-54 proteins. Then the Nogo-54 protein was purified by 
Ni
2+
-affinity chromatography under native conditions and subsequently purified 
by HPLC on a reverse-phase C8 column (Vydac). The whole expression and 
purification process and the purity of the purified protein were assessed by 
SDS-PAGE using 15% gel. 
15
N isotope-labeled Nogo-54 protein sample was prepared for heteronuclear 
NMR experiments followed the similar expression and purification procedures. 
 
3.7.2 Structural Characterization of Nogo-54 by CD 
 The structural properties of Nogo-54 were fist investigated by CD 
spectroscopy. As shown in Figure 3.7.1, the spectrum of Nogo-54 in 5mM 
phosphate buffer (pH 5.2) had a maximal negative peak at around 202 nm, which 
implied that Nogo-54 has a typical α-helix conformation. All the data were from 
three independent scans and were added and averaged. 
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Figure 3.7.1: Preliminary structural characterization of Nogo-54 by far-UV 
CD. Far-UV CD spectrum of Nogo-54 in 5 mM phosphate buffer (pH 5.2). 
 
3.7.3 NMR Structural Characterization of Nogo-54 
NMR HSQC experiment was used to further assess the structural properties of 




N NMR HSQC spectra of Nogo-54 
showed a well-separated HSQC spectrum (~1.8 ppm dispersed over 
1
H and ~20 
ppm dispersed over 
15
N dimensions), recommending their suitability for further 
NMR structure determination.  





N HSQC spectrum of Nogo-54 collected in 5 mM 
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 A pair of NMR spectra, 
15
N-edited HSQC-TOCSY and HSQC-NOESY was 
collected from a 
15
N -labeled Nogo-54 protein sample to obtain the preliminary 
backbone sequential assignment and 3D structural determination for Nogo-54. All 
the 54 residues were assigned except Pro18 whose HSQC peak could not be 
observed under the experimental conditions (Figure 3.7.3).  
 After finishing all the chemical shift assignment, secondary structure of 
Nogo-54 protein was calculated by Hα chemical shifts. Figure 3.7.4 showed that 
the secondary structure calculated by Hα. The deviation of Hα is negative in most 
regions, indicating that these regions are α-Helix.  
 
    




N HSQC spectrum of the Nogo-54 protein. 
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Figure 3.7.4: Nogo-54 chemical shift deviation of Hα provides insights in its 
secondary structure.  
 
 
3.7.4 NMR Structure Determination of Nogo-54 
 After backbone chemical shifts assignment of Nogo-54, the NOE assignment 
was done according to 
15
N-edited HSQC-TOCSY and HSQC-NOESY spectra and 
the NMR structure of Nogo-54 was calculated from the experimental NMR 
constraints by CYANA program (Guntert, 2004). Table 3.7.1 summaries the 
constraints used and structural statistics for the ten accepted CYANA structures of 
Nogo-54. As shown in Figure 3.7.5, Nogo-54 adopted a helical structure 
composed of two well-formed α-Helix spanning over residues 8-15 and 25-50, 
linked by a loop. If superimposed separately, both helixes were well refined. 
Furthermore, the first helix had long-range packing with the second one, showed 
by the long-range NOEs. Figure 3.7.6 summarizes NOE patterns critical for 
defining secondary structures. According to Figure 1.2.3, based on the dNN(i, i+2), 
dαN(i, i+3) and dαN(i, i+4) NOE patterns, it was very obvious that Nogo-54 had a 







R1 I6 Q11 G16 Q21 E26 E31 K36 A41 N46 E51
Chemical shift deviation of Hα 
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Table 3.7.1: NMR constraints used and structural statistics for the ten 
accepted CYANA structures of Nogo-54. 
 
  
NOE upper distance limits  
    Intra-residue 167 
    Sequential 212 
    Medium range 136 
    Long range  12 
      Total 527 
  
Dihedral angle restrains 85 
  
Final CYANA structures  
    CYANA target function 1.57±0.09Å 
    Distance restraint violations (>0.20Å) 0 
    Angle restraint violations (>5º) 0 
  
Ramachandran analysis  
    Residues in favored regions 96.3% 
    Residues in allowed regions 3.7% 
    Residues in outlier regions 0% 
  
Root mean square deviation (Å)  
   Residues 8-15 (the first helix) 0.075(backbone atoms) 
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Figure 3.7.5: NMR structure of Nogo-54. (A) The NMR structure of Nogo-54 of 
Medaka fish in the ribbon mode. (B) All ten accepted Nogo-54 structures 
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 Previous studies proposed that the charged pockets on the NgR surface might 
play an important role in interacting with Nogo-66 (Barton et al., 2003; He et al., 
2003; Lauren et al., 2007; Schimmele and Pluckthun, 2005). Therefore, the 
electrostatic potential surface of the fish Nogo-54 model was examined to identify 
the candidate residues for binding to NgR. Interestingly, as shown in Figure 3.7.7, 
the fish Nogo-54 contains unique charged patches. Putting the N-terminal short 
helix facing to the front, both the N-terminal helix and the C-terminal residues 
formed negative patches, while residues in the middle of the model has a positive 
patch. While a 180° rotation of the model showed a positive N-terminal patch and 
a negative patch in the middle of fish Nogo-54.  
 
           
Figure 3.7.7: The electrostatic potential surface of Nogo-54 in Medaka fish. 
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3.7.5 Discussion 
Nogo (RTN4) belongs to the reticulon family of membrane proteins, which is 
a eukaryotic gene family with ubiquitous expression and distinctive topological 
features (Oertle et al., 2003). Three different isoforms of Nogo, Nogo-A, -B and 
-C, are involved in a variety of functional processes including apoptosis, CNS 
neurite regeneration, neuron pathologies, vascular remodeling and so on. Two 
inhibitory domains of Nogo-A are responsible for the neurite growth inhibiting: 
The first one is a unique N-terminal region, which do not exist in Nogo-B and –C 
(Oertle et al., 2003). The second one is an extracellular 66 amino acid loop 
(Nogo-66) shared by all the three isoforms which can bind to the Nogo-66 
receptor family (NgR) consisting in three glycophosphatidylinositol 
(GPI)-anchored receptors (NgR1, NgR2 and NgR3) (Fournier et al., 2001; Li et al., 
2006; Li et al., 2004). Nogo-66 is an important region with multiple functions, 
especially in inhibiting of human CNS axonal regeneration, by interacting with 
NgR. Unfortunately, Nogo-66 itself was insoluble and unstructured. Previously, 
Nogo-54, a soluble form of Nogo-66 of human, was rationally designed and the 
NMR structure was solved (Li et al., 2008). It is not only buffer soluble, well 
structured but also able to mimic Nogo-66 in inhibiting neurite outgrowth. 
In contrary to human CNS, CNS in fish is able to regenerate axons. Previous 
study showed that the first inhibitory domain, Nogo-A-specific domain is lost in 
fish, and the second domain, Nogo-66 was modified so that Nogo does not impair 
axon regeneration (Abdesselem et al., 2009; Diekmann et al., 2005; Schweigreiter, 
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2008). Experiments showed that via binding to the same receptors, Nogo-66 in 
Zebrafish is growth permissive for both Zebrafish and mouse neurons in the 
Zebrafish optic nerve, while the Nogo-66 homolog in rat inhibits growth in both 




Figure 3.7.8: Structural model of human Nogo-54. (A) Structural model of 
human Nogo-54 in the ribbon mode, with Lys50, Arg53 and Arg54 side chains 
displayed in blue sticks; and Glu51 side chain in red sticks. (B) The electrostatic 
potential surface of human Nogo-54 with the charged patches not presented in 
Nogo-40 labeled (Li et al., 2008).  
 
 As shown in Figure 3.7.8A, Nogo-54 in human adopted a helical structure 
composed of three helices and with the long-range packing between the C-half of 
the middle helix and the last helix (Li et al., 2008). Compared with the human 
Nogo-54 NMR structure, the fish Nogo-54 NMR structure is quite different. As 
shown in Figure 3.7.5, Nogo-54 in Medaka fish also has a helical structure, while 
it only contains two helices and the long-range packing is between the first helix 
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and the N-half of the second helix.  
The crystal structure of the NgR ectodomain showed one potential Nogo-66 
binding site on NgR, which has characteristics of a negative cavity (Barton et al., 
2003; He et al., 2003; Lauren et al., 2007; Schimmele and Pluckthun, 2005). 
Previous studies also demonstrated that Lys50, Glu51, Arg53 and Arg54 of human 
Nogo-54 could form a large positive surface and it was responsible for the 
NgR-binding (Figure 3.7.8B). The NMR and mutation results showed that the four 
charged residues are crucial in binding with NgR to initiate the inhibitory action 
(Li et al., 2008). Compared to the human Nogo-54, fish Nogo-54 does not have 
this positive patch, while it still has the ability to bind with both fish and rat NgR 
(Abdesselem et al., 2009). Taken together with above results, it is possible that 
fish Nogo-54 bind to its NgR with a different region (e.g. the positive patch in the 
middle of Nogo-54) without inhibitory activity, which need to be further 
investigated. 
 The molecular interaction between Nogo-66 and NgR poses permissive or 
inhibitory effects on the CNS neuronal regeneration in different species; therefore 
the Nogo-66-NgR interface is an extremely promising target for design of 
molecules to treat CNS injuries. The availability of the Nogo-54 structure offered 
us rationales for deeply analyzing the different effects in different species. 
Furthermore, the Nogo-54 structure in fish may serve as a promising starting point 
for further design of therapeutics to enhance human CNS neuronal regeneration.  
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CHAPTER IV. Conclusion and Future Work 
 
Although all the solved Eph ligand-binding domain structures adopt the same 
jellyroll β-sandwich fold, their high-affinity ephrin-binding channels have their 
own unique features. By using crystallography and NMR spectroscopy, we 
determined the crystal structure of the EphA5 ligand-binding domain. Unlike the 









 in the J-K loop, the EphA5 
ligand-binding domain assumes helical conformations while the corresponding 
residues adopt a short β-sheet in EphA2, EphA4 and EphB2 in the free state. The 
EphA5 helical conformation in the J-K loop resembles the open form of the 
high-affinity ephrin-binding channel previously observed in Eph receptor LBDs in 
complex with ephrins. The existence of this helical conformation is also confirmed 
by NMR chemical shifts in solution. The uniqueness associated with the 
high-affinity ephrin-binding channel of EphA5 may be exploited for the 
identification of small molecules selectively targeting EphA5 with high affinity. 
To test the activity of the EphA5 LBD structure, two antagonistic peptides, 
WDC and WTF and one agonistic small compound, Doxazosin Mesylate was used. 
Their bindings with EphA5 LBD were studied by NMR spectroscopy, ITC and 
computer dockings. All the three components could bind to EphA5 LBD in the 
conserved ephrin-binding channels with different binding affinities.  
 NMR studies and MD simulations reveal that like the EphA4 LBD, the 
  139 
β-strands constituting the jellyroll β-sandwich fold are highly rigid but the loops 
can adopt multiple conformations exchangeable on the ps-ns time scale. Unlike 
the EphA4 LBD, the EphA5 LBD is characterized by unusually high dynamics 
over the D-E loop, which appears to result in an extensive exposure of the residues 
in the D and E strands over the min-hr time scale, as experimentally confirmed by 
the NMR H-D exchange results. On the other hand, Mode-free analysis of the 
relaxation data and CPMG-based relaxation dispersion measurements reveal that 
the EphA5 LBD lacks significant conformational exchanges on the µs-ms time 
scale.  
Based on the structural and dynamic results obtained, it appears that even in 
the unbound state the open form of the high-affinity ephrin-binding channel of 
EphA5 is highly populated. As a consequence, EphA5 is ready for binding 
ephrin-As and other ligands, such as antagonistic peptides or small molecules, 
without needing significant conformational exchanges on the µs-ms time scale. By 
contrast, the highly populated conformation of EphA4 in the unbound state is the 
closed form while the open form only represents a minor population. Therefore, 
ephrin binding to EphA4 is needed to shift the equilibrium from the closed to the 
open form, which occurs on the µs-ms time scale. The current results with EphA5 
thus strengthen the proposal derived from our studies on EphA4 that the binding 
of Eph LBDs to different ligands follows a conformational selection scenario 
[17,39], consequently highlighting the central role of protein dynamics in the 
bidirectional Eph-ephrin signaling.  
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The crystal structure of EphA7 ligand-binding domain was also solved. 
Unlike EphA5, this crystal structure of EphA7 has six molecules in one 
asymmetric unit (AU). It bears a highly similar jellyroll folding architecture 
composed of 11 antiparallel beta-stands to the previous determined ligand binding 
domains structures. While by conducting the H-D exchange experiments and 
mapping the binding site of Doxazosin Mesylate, we can tell that the protein 
dynamic property and binding affinity of EphA7 is different from EphA5. When 
binding to Doxazosin Mesylate, although Dox could bind to both ephrin-binding 
channel of EphA7 and EphA5, it clearly binds to EphA5 with a much higher 
affinity and with more residues involved. The results of H-D exchange 
experiments also showed that although EphA7 and EphA5 have the same jellyroll 
folding architecture, dynamic properties of their loop regions are quite different. It 
suggests the ligand-binding domain of EphA7 is more rigid than EphA5 in a 
min-hr time scale, although its loop regions are also very flexible. Compared to 
the “open” form that EphA5 adopts most of the time, EphA7 may adopts a “close” 
form when it is in the unbound state. A previous study showed that co-expression 
of a truncated form of EphA7 suppresses tyrosine phosphorylation of the 
full-length EphA7 receptor and shifts the cellular response from repulsion to 
adhesion in vitro (Holmberg et al., 2000). And a soluble splice variant of EphA7 
(EphA7
TR
) can interfere with full-length EphA2 and blocks oncogenic signals in 
lymphoma cells (Oricchio et al., 2011). This study proved that EphA7 receptor 
could act as a tumor suppressor in follicular lymphoma with immediate 
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therapeutic potential. With the availability of EphA7 LBD crystal structure, the 
interaction characterizations of above studies could be invested deeper in a 
different aspect. Furthermore, the design of antagonistic/agonistic molecules with 
high affinity and specificity might be achieved by targeting a special dynamic 
state of the Eph LBDs, although they have the same jellyroll β-sandwich fold. 
 The structure of the buffer-soluble form of Nogo-66, Nogo-54 was solved by 
NMR spectroscopy. Nogo-54 adopted a helical structure composed of two 
well-formed α-Helix, linked by a loop. If superimposed separately, both helixes 
were well refined. Furthermore, the first helix had long-range packing with the 
N-term half of the second one, showed by the long-range NOEs. Unlike Nogo-54 
in fish, the protein in human adopted a helical structure composed of three helices 
and with the long-range packing between the C-half of the middle helix and the 
last helix (Li et al., 2008). The crystal structure of the NgR ectodomain showed 
one potential Nogo-66 binding site on NgR, which has characteristics of a 
negative cavity. The C-terminal residue, Lys50, Glu51, Arg53 and Arg54 of 
human Nogo-54 could form a large positive surface, which could bind to the 
negative cavity of NgR. Compared to the human Nogo-54, fish Nogo-54 does not 
have this positive patch in its N-terminal, while it still can bind to both fish and rat 
NgR. These results suggest that fish Nogo-54 bind to its NgR with a different 
region and without inhibitory activity. To further understand this phenomenon, the 
characteristics of the binding between NgR with both human and fish Nogo-54 
could be studied by NMR titration and ITC experiments. After mapping their 
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binding sites on the structure of the proteins, site mutation of each protein could 
be designed to specify the detailed interacting site. By analyzing the specific 
binding site, protein interactions could be mimic by docking. The protein dynamic 
properties of the unbound proteins and complexes can be achieved by NMR 
spectroscopy, MD simulation and H/D exchange at the same time. Based on above 
investigation, we might be able to explain why human CNS has the neuronal 
regeneration inhibition while fish CNS does not. And it may serve as a promising 
starting point for further design of therapeutics to enhance human CNS neuronal 
regeneration. 
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